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Systemic administration of mesenchymal stem cells (MSC) has been shown to be 
efficacious in ameliorating disease conditions in animal models and clinical trials. 
However the mechanism underlying MSC homing to injury sites has not been fully 
elucidated. This study aims to investigate the factors which may play a role in MSC 
homing and migration to injury sites. The homing mechanism of MSC is hypothesized to 
be similar to that of leukocyte recruitment, a multi-step process involving a number of 
factors. Our study showed that MSC responded positively in an in vitro transwell assay to 
platelet-derived growth factor AB (PDGF-AB), a growth factor secreted by activated 
platelets found in injury sites. However, in the presence of TNFα, the response of MSC to 
PDGF-AB was inhibited. Pre-treating MSC with TNFα for 24 hours not only rescues this 
inhibition but also enhanced both MSC basal migratory capabilities and their response 
towards PDGF-AB.  
Next, we showed that VLA4 (α4β1 integrin) expressed on MSC mediates interaction with 
endothelial cells under defined flow conditions. However, TNFα pre-treatment of MSC 
inhibited the MSC-endothelial interactions unlike the enhancement seen in migration. 
This was inconsistent with published studies showing that TNFα pre-treated MSC had 
increased homing capacity in animal models. However, FACS analysis of TNFα treated 
MSC did not reveal any change in expression of surface adhesion molecules with the 
exception of ICAM-1 and VCAM-1. Hence, we asked if the presence of immune cells 
that were recruited to injury sites could an explanation to the findings in the literature. 
We manage to rescue this inhibition by introducing fresh monocytes but not neutrophils 
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into the flow chamber together with the TNFα pre-treated MSC. During the assay, MSC 
were observed to interact physically with the monocytes. Unlike monocytes, matured 
neutrophils lack VLA4 expression. Therefore, these MSC-monocyte interactions were 
likely to be between VLA4 expressed on monocytes and VCAM-1 expressed on TNFα 
pre-treated MSC.  
These data collectively suggest the involvement of PDGF-AB, monocytes in MSC 
recruitment and the potential role of TNFα in mediating the cross-talk between various 
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1.1 Mesenchymal stem cells 
 Mesenchymal stem cells (MSC), otherwise known as bone marrow stromal cells, 
was discovered by Friedenstein who noticed that transplantation of bone marrow cells 
resulted in osteogenesis (Friedenstein et al., 1966; Friedenstein et al., 1974). Subsequent 
studies revealed that these cells are multipotent in nature. They are able to differentiate 
into osteocytes, chondrocytes or adipocytes depending on environmental cues (Pittenger 
et al., 1999). In recent years, numerous studies have also shown that MSC possess the 
potential to transdifferentiate into cells of both the ectodermal  (Kopen et al., 1999) and 
endodermal lineages (Aurich et al., 2009). Figure 1.1 shows our current understanding of 
the differentiation potential of MSC. MSC are classically accepted to be able to 
differentiate into cells of the mesodermal lineage, such as chondrocytes, osteocytes or 
adipocytes, under both in vivo and in vitro conditions (solid arrows). There are also a 
number of studies suggesting that MSC also has a potential to cross differentiate into 
cells of the ectodermal and endodermal lineages (dashed arrows). However, this 
phenomenon has only been induced under in vitro conditions and it is still unclear if 
MSC can transdifferentiate in this manner under in vivo conditions. 
 Other than its multipotency, MSC also possess other properties which makes it an 
attractive candidate for tissue replacement therapy. One of these properties is the immune 
privileged status of MSC. Evidence of MSC being able to avoid host rejection was first 
shown in a xenogeneic study where human MSC were transplanted into an immune-
competent sheep. The human MSC underwent engraftment and persisted for as long as 13 
weeks in a xenogeneic environment without signs of rejection (Liechty et al., 2000). 
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Subsequent studies revealed that the low immunogenicity of MSC might be due to their 
low MHC-I expression and lack of MHC-II or other stimulatory molecules, which 
allowed them to escape immune surveillance (Barry et al., 2005; Le Blanc et al., 2003). 
MSC also possess the ability to modulate the immune system via cell contact and 
secretion of soluble factors (Uccelli et al., 2008). Studies have shown that MSC are able 
to suppress various aspects of the immune system; such as the inhibition of T-cell 
proliferation, inhibition of inflammatory cytokine secretion by macrophages, and 
supporting regulatory T cell production (Newman et al., 2009). These unique properties 
of MSC would thus allow them to avoid host rejection and at the same time prevent graft-
versus-host complications. In addition, MSC were also documented to suppress 
inflammation and aid in the resolution of injury (Aronin and Tuan, 2010). With their 
multipotency and immune-modulatory properties, MSC show great potential in 
regenerative medicine. 
 Since the first infusion of MSC into animal subjects, much work has been done to 
elucidate the mechanism underlying the therapeutic effects of MSC. Being a stromal stem 
cell, early works focused on whether MSC can function as replacement cells for 
connective tissues such as bones. This serves as the rationale for the study by Horwitz et 
al, where donor bone marrow extracts were used to treat children afflicted with 
osteogenesis imperfecta, a bone disorder (Horwitz et al., 1999). Similarly, researchers 
tried using MSC to treat other genetic diseases which requires bone marrow stem cells 
replacement, such as Hurler syndrome and metachromatic leukodystrophy (Koc et al., 
2002) which causes skeletal and neurological defects respectively in children. These 
studies suggest that the engraftment and probably differentiation of MSC is necessary for 
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their therapeutic effects. However, recent studies showed that most transplanted MSC 
persists for less than one week after injection into mice (Lee et al., 2009; Zangi et al., 
2009). The short life-span of these administered MSC may suggest that their therapeutic 
effects are due to what they secrete on-site as opposed to cell differentiation (Wu et al., 
2007). Although the exact mechanisms behind the therapeutic properties of MSC remain 













Figure 1.1 Possible fates of a bone marrow mesenchymal stem cell 
MSC has the potential to differentiate into various cell types from the three distinct germ 
layers. Solid arrows depict the processes which can occur under both in vivo and in vitro 
conditions while the dotted arrows depict processes which have been proven only under 
in vitro settings. 




1.1.1 MSC of fetal origin 
 Other than the bone marrow, MSC have also been isolated from extra-marrow 
sites such as skin, muscle and adipose tissues from adults (Musina et al., 2007; Romanov 
et al., 2005; Williams et al., 1999). Like bone marrow derived MSC, MSC isolated from 
these extra-marrow sites were also able to differentiate into cells of the mesenchymal 
lineage. These extra-marrow sites are more accessible compared to the bone marrow for 
MSC extraction and isolation. Furthermore, the fact that MSC can be isolated from adults 
would mean that their use will not be accompanied by the numerous ethical issues which 
came with the research on embryonic stem cells (Vogelstein et al., 2002). 
 Most work published on MSC were done on adult cells until a pilot study by 
Guillot et al showed that human fetal MSC (hfMSC) is also a viable cell source (Guillot 
et al., 2007). In the study, fetal MSC from the first trimester was shown to express 
pluripotent stem cell markers such as Oct-4, Nanog, SSEA-1 and SSEA-2 which were 
found to be absent in adult MSC. In addition, hfMSC expand more rapidly and senesced 
later in culture compared to adult MSC due to higher telomerase activity (Guillot et al., 
2007). Studies done in animal models also showed that using fetal-derived cells were 
more advantageous than adult cells in terms of both engraftment and treatment efficacy. 
For instance, MSC from murine fetal liver out competed adult bone marrow MSC in 
engraftment by 10-folds following in utero transplantation into SCID mice (Taylor et al., 
2002). In another comparative study, murine fetal liver MSC showed higher myogenic 
repair properties as compared to adult bone marrow MSC  (Fukada et al., 2002). Gene 
expression profiling for adult and fetal MSC revealed that there were more transcripts 
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involved in cell cycle promotion and DNA repair mechanism in fetal MSC compared to 
adult MSC (Gotherstrom et al., 2005). Furthermore, there were fewer transcripts in fetal 
cells involving the differentiation of MSC and cell cycle arrest as compared to adult cells 
(Gotherstrom et al., 2005). Fetal MSC were also shown to have higher gene expression 
for osteogenesis and upon differentiation, fetal MSC-differentiated cells secreted more 
calcium than adult cells (Guillot et al., 2008). Therefore, the genes that were highly 
expressed in hfMSC allowed the cells to have greater potential for both proliferation and 
differentiation. 
 With fetal MSC being comparable if not better than adult MSC in terms of quality 
and efficacy (Gotherstrom et al., 2005; Guillot et al., 2008), MSC of fetal origin are 
gradually receiving more attention from researchers and clinicians alike. Fetal MSC can 
be isolated, readily expanded and stored for future use (Secco et al., 2008). Due to MSC 
being immune-privileged (Aronin and Tuan, 2010), patients undergoing MSC 
transplantation need not go through an additional procedure to harvest their own MSC for 
an autologous transplantation. This will save both costs and time especially if the patient 
is suffering from acute ailments such as myocardial infarction. Furthermore, studies have 
also shown that the number of stem cells harvested from the bone marrow declines with 
age (Tokalov et al., 2007). Therefore, MSC of fetal origin is proving to be a more 
attractive cell source as compared to adult bone marrow.  
 
1.1.2 Potential applications of MSC 
 Following the isolation of MSC from bone marrow, the cells were terminally 
differentiated under in vitro conditions into cell types such as pancreatic islet cells 
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(Timper et al., 2006), cardiomyocytes (Fukuda, 2003), hepatocytes (Aurich et al., 2009) 
and neurons (Scintu et al., 2006). These studies suggest that MSC could possibly be used 
as a source for cell replacement therapies.  As mentioned earlier, the work of Horwitz et 
al, provided insights as to how MSC could be used after he successfully transplanted 
allogenic bone marrow into children with osteogenesis imperfecta (Horwitz et al., 1999), 
a genetic disease which results in Type-I collagen deficiency (Rauch and Glorieux, 2004). 
After the MSC transplantation, patients showed improved bone mineralization and 
reduced frequencies of bone fractures. This suggests that the engrafted MSC can 
differentiate into osteoblasts and successfully treat osteogenesis imperfecta. 
 Another area where MSC can be used therapeutically is in the suppression of 
Graft-versus-host disease (GVHD) from bone marrow transplants following radiation. 
GVHD is a devastating condition where the transplanted marrow produces immune cells 
that attack various organs in the recipient (Tabbara et al., 2002). Co-administration of 
MSC with hematopoietic stem cells (HSC) have been shown to reduce the severity of 
GVHD in addition to improving the engraftment of the latter (Jaganathan et al., 2010). In 
fact, this particular application is already going into Phase II clinical trials where patients 
receiving bone marrow transplant also receive bone marrow derived MSC from donors. 
Results showed that the procedure was safe and patients survival rate following MSC 
cotransplantation was 53% higher compared to patients who did not receive the co-
treatment (Lazarus et al., 2005). Similarly, results from a more recent study have also 
showed that majority of the patients responded favourably to MSC-transplantation 
treatment and post-transplantation mortality was reduced (Le-Blanc et al., 2008).  
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 MSC transplantation can also be used in treatment of cardiovascular diseases such 
as myocardial infarction and ischemia. In two independent studies involving animal 
models, direct transplantation of MSC to infarcted cardiac tissues was shown to improve 
cardiac performance (Olivares et al., 2004; Silva et al., 2005). Compared to sham-treated 
animals, animals treated with MSC showed regeneration of myocardium and de novo 
angiogenesis. Subsequent functional and histological examination of the heart revealed 
that MSC-treated animals were comparable to uninjured control animals. In both cases, it 
was suggested that recovery was in part due to the angiogenic effect induced by MSC 
transplantation. 
 The immunomodulatory ability of MSC has been shown to alleviate many 
autoimmune disorders (van Laar and Tyndall, 2006). In a recent study, MSC was 
observed to home to the spleen of mice with experimental autoimmune myasthenia gravis 
(EAMG) following intravenous injection (Yu et al., 2010). Within the spleen, MSC 
inhibited the proliferation of acetylcholine receptor (AchR) specific lymphocytes, thus 
reducing the symptoms of EAMG. Other than EAMG, MSC therapy also shows much 
promise in the treatment of rheumatoid arthritis (RA). MSC have been shown to regulate 
immune tolerance in human subjects diagnosed with RA (Gonzalez-Rey et al., 2010). In 
this study, the presence of MSC suppressed both the proliferation of effector T cells and 
their production of inflammatory cytokines. In addition, the study also showed the 
presence of antigen specific regulatory T cells which were activated by MSC.  
 MSC have been shown to home to tumour sites (Spaeth et al., 2008). In many 
ways, the microenvironment of tumour stroma resembles that of injured sites. Soluble 
factors secreted by the tumour stroma have also been documented to attract MSC 
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chemotactically (Dwyer et al., 2007). Thus, this propensity of MSC to home to tumour 
sites has been used to deliver therapeutics to tumour sites (Hung et al., 2005). 
Administration of genetically modified MSC which secretes IFN-β to xenografted 
tumours in mice were able to suppress the growth of pulmonary metastases (Studeny et 
al., 2004). Another study employed a similar model to target xenografted glioma in mice. 
Not only were the administered MSC able to track the glioma, mice treated with INF-β 
secreting MSC showed a higher survival rate (Nakamizo et al., 2005).  
 From the above examples, the potential uses of MSC as a cellular therapeutic can 
be clearly seen. However, the effectiveness of the application may vary between different 
parts of the body depending on accessibility to the injury site. Some anatomical locations, 
such as inflamed joints in patients with rheumatoid arthritis, are suitable for direct 
injection whereas locations such as the brain in stroke patients are not. Therefore, the 
mode of administration is an important factor to be considered in the use of MSC as a 
cellular therapeutic. 
 
1.1.3 Mode of administration 
 There are a few ways of introducing ex vivo expanded MSC into subjects. 
Different routes of administration have varying degrees of invasiveness and specificity. 
The three main routes of administration in studies involving animal models are namely, 
intra-peritoneal (Secchiero et al., 2010), intravenous (Osaka et al., 2010) and direct on-
site injection (Ji et al., 2004). On-site administration offers the highest specificity out of 
all three routes with minimal infiltration to non-specific sites. However, due to the 
invasiveness of the procedure, there may be additional tissue damage and multiple dosing 
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cannot be applied unlike intra-peritoneal or intravenous injections. Intra-peritoneal 
injection is relatively less invasive compared to on-site injection but there is little control 
over the distribution of the administered cells. A study showed that MSC accumulates 
mainly in the visceral organs such as the liver, spleen, kidneys and lungs but not in the 
central nervous system (CNS) after intra-peritoneal administration in rats (Gao et al., 
2001). Thus, this limits the use of this route of administration where MSC are required to 
be recruited to areas within the CNS such as intracranial stroke (Ji et al., 2004). On the 
other hand, intravenously administered cells have been shown in animal models to get 
passively trapped in pulmonary capillaries (Schrepfer et al., 2007). This is largely due to 
the relative difference in the size of the administered MSC and capillary lumen size in the 
animals. This phenomenon was only observed in animals but not in human subjects 
receiving MSC transfusion (von Bonin et al., 2008). Studies have also shown that i.v. 
administered MSC were able to home specifically to injury sites with minimal infiltration 
into non-injured areas (Chen et al., 2001; Horwitz et al., 2002; Ortiz et al., 2003). 
 As discussed above, the invasiveness of the MSC administration process is 
inversely related to the specificity of the procedure. Direct on-site injection offers the 
highest level of specificity but the procedure is also highly invasive. This is important 
when dealing with patients who are recovering from major afflictions such as myocardial 
infarction or cerebral ischemic stroke as this will increase the risks if surgery is needed 
for the administration of MSC to them. While intravenous injection is the safest, the 
success of this method depends heavily on the ability of the injected cell to home 
specifically from circulation to the site of interest. The process of cell homing in turn 
relies heavily on the adhesion molecules and chemokine receptors expressed on MSC. 
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Thus, there is a need to optimize the homing of MSC following intravenous 
administration in order for the patients to fully benefit from this form of cellular therapy. 
   
1.2 Recruitment of cells during inflammation 
 Currently, the most well-studied recruitment process is that of leukocyte homing 
in response to inflammatory signals (Figure 1.2). This is a multi-step process involving 
various adhesion molecules expressed on both the inflammation-activated endothelial 
cells and leukocytes (Dunon et al., 1996). Firstly, the homing leukocytes will have to 
slow down by tethering on the endothelial cells. Subsequently, activated adhesion 
molecules on leukocytes will establish tight adhesion with their counter ligands expressed 
on endothelial cells. The final step involves the extravasation of the leukocytes across 
endothelial tight junctions into the interstitium. During the onset of inflammation or 
infection, systemic level of G-CSF will be increased, serving as cues for the mobilization 
of leukocytes from the bone marrow (Gregory et al., 2007). At the injury site, various 
cytokines and chemokines such as IL-1α, TNFα and IL-8 will be released by damaged 
cells (Bronneberg et al., 2007). These soluble mediators will activate the endothelium 
present at the injury site and mediators such as IL-8 also serve as chemoattractant for the 
mobilized immune cells. This process of leukocyte recruitment serves as a basis for MSC 
recruitment studies and it is believed that both cell-types share a certain amount of 




1.2.1 Key players involved in leukocyte recruitment 
 During the first step of this process, leukocytes will be ‘captured’ by the activated 
endothelium where they will tether and roll on. These tetherings are mediated via weak 
interactions between L-selectin expressed on leukocytes and CD34 expressed on 
endothelial cells (Imhof et al., 1995). Activated endothelium also express P-selectin and 
E-selectin, which mediates the rolling process through interactions with P-selectin-
dependent ligand (PSGL)-1 expressed on leukocytes (Alon et al., 1994). Rolling allows 
leukoctyes to accomplish two things, firstly, to slow down from the rapid flow of the 
blood and secondly, to activate surface integrins which are responsible for establishing 
firm adhesion to the endothelium (Simon et al., 1995). During rolling, the leukocytes are 
likely to encounter chemokines such as IL-8 that is secreted by activated endothelial cells 
(Utgaard et al., 1998). Binding of these chemokines to the chemokine receptors expressed 
on homing leukocytes results in the biochemical signaling through small G-proteins, 
otherwise known as the ‘outside-in’ signaling which ultimately leads to integrin 
activation (Laudanna et al., 1996). Following the activation of surface integrins, 
leukocytes are now primed for the next step of their recruitment. 
 In this phase of the recruitment cascade, leukocytes will bind firmly and arrest on 
the endothelium. Different leukocytes utilize different integrins to bind cell adhesion 
molecules (CAMs) expressed on endothelial cells since the expression of integrins on 
leukocytes differs with its cell type. For instance, neutrophils are documented to express 
only αLβ2 (LFA-1) integrins but not α4β1 (VLA4) integrins (Kirveskari et al., 2000) 
while lymphocytes and monocytes express both LFA1 and VLA4 (Walzog and 
Gaehtgens, 2000). Following chemokine-induced activation, conformational changes in 
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the integrin molecules will allow them to bind to their respective ligands with high 
affinity resulting in cell arrest (Laudanna et al., 2002).  
 After the formation of a stable adhesion, the leukocyte is now prepared to pass 
through the endothelial layer into the extravascular tissue. At endothelial cell junctions, 
leukocytes will first induce a transient loss of tight junction proteins (Reijerkerk et al., 
2006; Xu et al., 2005). Next, leukocytes will utilize surface proteins such as junctional 
adhesion molecule-A (JAM-A) and PECAM-1 expressed on themselves and endothelial 
cells to mediate the diapedesis process (Corada et al., 2005; Mamdouh et al., 2003). Once 
in the interstitium, the leukocyte will migrate along a concentration gradient of 
chemokines to the injury site. This migratory process is mainly mediated by integrins 















Figure 1.2 The multi-step recruitment paradigm of leukocyte recruitment 
The early process of leukocyte recruitment is mediated mainly by selectins expressed on 
activated endothelial cells interacting with carbohydrate residues expressed on activated 
leukocytes. Subsequently, leukocytes will establish tight adhesion with the endothelium 
via integrins. The final step of the process involves the leukocyte transmigrating across 
the endothelium into the interstitium. 
 
1.2.2 Current understanding of MSC recruitment to inflammatory sites 
 As mentioned in the previous section, leukocytes are well known for being able to 
home to inflammatory and injury sites. Since many studies have also shown that MSC are 
also capable of selectively homing to these sites, it is probable that the process of MSC 
recruitment share some similarities with that of leukocyte recruitment. However, there 
are some obvious differences in the types of adhesion molecules expressed on MSC as 
compared to various leukocyte subsets. Unlike leukocytes which utilize L-selectin for the 
initial rolling step on the activated endothelium, MSC do not express L-selectin 
(Sackstein et al., 2008) nor selectin ligands (Ruster et al., 2006). Another adhesion 
molecule that MSC lacks is CD31 (PECAM-1) which has been documented to be 
involved in transendothelial migration of leukocytes (Muller et al., 1993).  
 Although MSC lacks selectin and selectin ligand expression, adhesive pathway 
has been implicated in MSC recruitment. The importance of selectins in MSC 
recruitment was first suggested by the works of Ruster et al. Using intravital microscopy, 
the study showed that intravenously injected MSC rolled along the vessel walls within 
the ear veins of wild-type mice but not in P-selectin knock-out mice (Ruster et al., 2006). 
The study further showed in an in vitro assay that MSC have reduced rolling under 
defined flow conditions on HUVEC treated with a function blocking P-selectin antibody. 
However, unlike leukocytes, MSC do not express PSGL1 or other known selectin ligands. 
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Therefore, it may be possible that a novel selectin ligand exists on MSC which is capable 
of mediating rolling on P-selectin expressed on endothelial cells. However, a similar 
preliminary study conducted in our lab showed that human fetal MSC was unable to 
interact with P-selectin under defined flow conditions (Data not shown). This may 
suggest that the novel P-selectin ligand (as proposed by Ruster et al) may be differentially 
expressed on MSC from different sources. Nonetheless, these data does not negate the 
possibility that MSC may also roll on endothelial cells like leukocytes during the initial 
stage of their recruitment process. As the MSC roll on the activated endothelium, they 
will encounter chemokines which will bind to their cognate receptors expressed on MSC. 
This ‘outside-in’ signaling is likely to result in downstream events such as integrin 
activation and affinity maturation (Laudanna et al., 2002). 
 Chemokines and their corresponding receptors are well documented to recruit 
leukocytes to inflammation and injury sites (Murdoch and Finn, 2000). Since MSC are 
shown in various studies to express chemokine receptors such as CCR1, CCR4, CCR6, 
CCR7, CXCR4, CXCR5, CXCR6, CX3CR1, this would suggests that they can respond 
to their cognate ligands (Honczarenko et al., 2006). In fact, chemokine-mediated MSC 
migration has already been shown under both in vivo and in vitro conditions (Ji et al., 
2004; Ponte et al., 2007). There was a study which co-cultured pancreatic islet cells with 
MSC in an in vitro transwell assay. The pancreatic islet cells in the bottom chamber were 
able to attract MSC seeded in the upper transwell insert. Interestingly, two soluble factors, 
CX3CL1 and CXCL12 were identified for this chemotactic effect seen in MSC (Sordi et 
al., 2005). This suggests that different chemokines may act individually or together as 
signals for MSC to home to specific organs within the body. However, studies have also 
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shown that the chemokine receptors expressed in MSC are either lost after a few passages 
in vitro (Reviewed by Prockop, 2009) or are only found at the intracellular level (Brooke 
et al., 2008). For example, the surface expression of CXCR4 is still a topic under debate. 
While some studies have reported high expression of this chemokine receptor on MSC 
(Honczarenko et al., 2006; Ponte et al., 2007), others were only able to show low surface 
expression (Brooke et al., 2008; Wynn et al., 2004). Furthermore, there were also studies 
that showed an increase in CXCR4 expression after MSC were exposed to shear stress 
(Ruster et al., 2006) or with cytokine treatment (Shi et al., 2007). Thus, more work is 
required to elucidate the regulatory mechanism underlying the regulation of chemokine 
receptor expression.  
 As mentioned earlier, chemokines are chemoattractants which activate integrins 
via biochemical signaling. Integrins and their activation are documented to be vital in the 
transendothelial migration of leukocytes. Therefore, it is a fair assumption that integrins 
also play similar roles in MSC recruitment. Many studies have been done on 
characterizing the surface expression of integrins and various adhesion molecules and 
their functionality on MSC. The studies unanimously showed that MSC expresses α1, α2, 
α3, α4, α5, α6, αV, β1, β3, and β4 as well as other adhesion molecules such as ICAM-1, 
ICAM-3, VCAM-1 and ALCAM-1 (Kemp et al., 2005; Majumdar et al., 2003). Beta 1 
integrin in particular, was shown by Ruster et al to have an important role in MSC 
recruitment (Ruster et al., 2006). The study showed that MSC were unable to establish a 
tight adhesion with endothelial cells via VLA4 following treatment with blocking 
antibodies to β1. Similarly, when endothelial cells were treated with blocking antibodies 
to VCAM-1, the counter ligand for VLA4, MSC adhesion was also reduced. Consistent 
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with this, we were also able to show in our preliminary studies that hfMSC can bind to 
immobilized VCAM-1 under defined flow conditions (Unpublished data). These data 
thus highlights the importance of VLA4/VCAM-1 interactions in the process of MSC 
recruitment.  
 The final step of MSC homing will require the MSC to breach the endothelial 
barrier and transmigrate across the endothelium. Chen et al, showed that intravenously 
administered MSC was able to cross the blood brain barrier into ischemic brain tissue of 
rats (Chen et al., 2001). Another recent study also showed that MSC could transmigrate 
across the cardiac endothelium into the surrounding injured myocardium following intra 
coronary injection in a porcine model (Hung et al., 2005). Microscopic evidence of MSC 
actively transmigrating across the endothelium was first provided through the works of 
Schmidt et al (Schmidt et al., 2006). They showed that co-culturing of MSC with 
embryonic stem (ES) cell-derived endothelial cells resulted in the MSC integrating into 
the endothelial monolayer, which was presumed to be part of the transmigration process. 
Furthermore, the authors also provided images of MSC transmigration through a capillary 
of an isolated mouse heart using confocal microscopy (Schmidt et al., 2006). These 
works suggest that MSC, under both in vivo and in vitro conditions, can establish a firm 
adhesion and possess the ability to transmigrate across the endothelium. 
 Most studies on MSC recruitment are focused on the interactions between MSC 
and endothelial cells. However, under an in vivo setting, MSC are not likely to be the 
only cell type that will home to an inflammation or injury site. Many studies have 
documented the homing of leukocytes into injury sites such as the involvement of 
neutrophils in myocardial infarction (Bell et al., 1990), T-cells in rheumatoid arthritis 
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(Rezzonico et al., 1998) and polymorphonuclear leukocytes in ischemic stroke (Armin et 
al., 2001; Ritter et al., 2000). Thus, despite our increased understanding of MSC homing 
results seen in pre-clinical trials and animal studies, the relationship between MSC and 
leukocytes homing to injury sites largely remains unelucidated. 
 
1.2.3 TNFα and MSC recruitment 
 TNFα is a 17 kDalton inflammatory cytokine that is produced mainly by 
mcarophages during infection and injury (Beutler and Cerami, 2003). After its release, 
TNFα will activate nuclear factor kappa B (NFkB) signaling which, will in turn up-
regulate the production of other inflammatory cytokines such as IL-6 and IL-1 (Li et al., 
1999). In addition, TNFα will also increase the expression of adhesion molecules on 
endothelial cells which promotes the adhesion of leukocytes. Therefore, it is likely that 
TNFα will also contribute to the adhesion and engraftment of MSC to inflammatory sites 
in a similar fashion. 
 Under an in vitro setting, TNFα have been shown to be able to augment the 
migratory response of MSC (Ponte et al., 2007). In the study, TNFα treatment of MSC 
was able to increase spontaneous migration and FCS-induced migration by 71% and 
170% respectively. In addition, TNFα was also able to enhance MSC response towards 
chemokines such as SDF-1, RANTES and MDC by more than two folds. However this 
enhancement was not seen in the presence of most growth factors tested in the study 
(EGF, IGF-1, PDGF, FGF-2 and angiopoietin-1), suggesting some specificity in the 
actions of TNFα on MSC response to soluble factors. Another study demonstrated 
enhanced migration of TNFα–treated MSC under in vivo conditions (Kim et al., 2009). 
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The TNFα-treated MSC was showed to have a much higher retention and engraftment 
rate in ischemic murine heart as compared to untreated cells. In addition, rats treated with 
TNFα-treated MSC had a greater improvement in cardiac output compared to mice 
treated with control cells. Thus, TNFα priming of MSC is not only able to enhance their 
migration but also their therapeutic effects.  
  
1.3 Objectives of study 
 In this study, we hypothesized that TNFα can enhance the ability of MSC to 
interact with the endothelium. In addition, we also hypothesized that leukocytes are 
involved during the process of MSC recruitment. To date, there is little information on 
how the presence of homing leukocytes may affect MSC recruitment. We felt that this 
was an important aspect as leukocyte recruitment to injury and inflammatory sites are 
integral to wound healing. The project aims to elucidate the steps in which MSC is 
recruited to an injury site following intravenous administration and how TNFα and the 
presence of leukocytes can augment the process.  
 TNFα-treatment of MSC has been shown to enhance recruitment and migration 
under both in vitro and in vivo conditions. Thus, the first objective of the study is to 
identify any change in expression of adhesion molecules after TNFα-treatment that may 
provide an explanation for the enhanced recruitment. To achieve this, we will compare 
the expression of integrins and other adhesion molecules as well as surface receptors to 
chemokines and growth factors between control (untreated) and TNFα-treated MSC. 
 During the onset of acute inflammation, blood neutrophils are usually the first cell 
type to be recruited, followed by mononuclear cells such as monocytes. Many studies 
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have documented the homing of leukocytes into injury sites such as the involvement of 
neutrophils in myocardial infarction (Bell et al., 1990), T-cells in rheumatoid arthritis 
(Rezzonico et al., 1998) and polymorphonuclear leukocytes in ischemic stroke (Armin et 
al., 2001; Ritter et al., 2000). The studies reviewed in the previous sections usually 
administer MSC shortly after the induction of an injury, implying that the MSC will have 
a high chance of encountering leukocytes which are also responding to the injury. The 
second objective will be to study the possible interactions between MSC and leukocyte at 
the endothelial surface. For this purpose, we will be utilizing a parallel plate flow 
chamber system to examine the interactions between MSC, leukocytes and endothelial 
cells under defined flow conditions. 
 To date, the role that chemokines play in cell recruitment has been well-
established. Growth factors on the other hand are more implicated in the growth and 
survival signals for cells. However, little information exists on how they affect 
recruitment of cells to injury site. Platelet-derived growth factors are produced by 
activated platelets and play an important role in wound healing. Thus we hypothesized 
that PDGF-AB (the dominant PDGF isoform secreted by platelets) will play a role in the 
recruitment and migration of MSC. Our third objective will be to study the effects of 
PDGF-AB on MSC migration and how this process could be regulated by TNFα. For this 
purpose, we will be utilizing an in vitro transwell system as well as a wound healing 
assay. 
 The outcome of this study will contribute to our understanding of mechanism 
underlying MSC homing and recruitment to injury sites following intravenous 
administration. More specifically, the study will shed light on how homing leukocytes 
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and pre-treatment of MSC with TNFα might affect their recruitment. The information 
obtained from this study may potentially be integrated with existing clinical data to 
further improve and optimize MSC delivery via intravenous administration. 
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2. Materials And Methods 
2.1 Common reagents and materials 
Complete DMEM medium used for the culture and maintenance of mesenchymal 
stem cells (MSC) comprised of Dulbecco’s Modified Eagle’s Media (containing 
4.5gram/L of glucose, DMEM+GlutaMAX
TM
, Gibco) supplemented with 10% fetal 
bovine serum (FBS, Sigma-Aldrich), 100 U/ml Penicillin and 100 μg/ml Streptomycin 
(Gibco). Complete EGM-2 medium (Clonetics) was used for human umbilical vein 
endothelial cell (HUVEC) culture. Hank’s Balanced Salt solution (HBSS) without Ca2+ 
and Mg
2+
 (Sigma-Alrich) was used for the washing of cells prior to both medium change 
and cell detachment. The concentration of trypsin (Gibco) used for the detachment of 
MSC and HUVEC are 0.005% and 0.02% respectively unless otherwise stated. DMEM 
wash buffer comprising of Dulbecco’s Modified Eagle’s Media (containing 4.5gram/L of 
glucose, Sigma-Alrich) supplemented with 5% fetal bovine serum (FBS, Gibco) was used 
for the neutralization of trypsin following cell detachment and the resuspension of cells 
for FACS staining. For HUVEC, M199 wash buffer comprising of M199 media (Gibco) 
supplemented with 10% fetal bovine serum (FBS, Gibco), 25mM HEPES (Sigma-Alrich), 
1X L-Glutamin (Gibco), 100 U/ml Penicillin and 100 μg/ml Streptomycin (Gibco) was 
used for the same purpose. All disposable culture wares for MSC culture were primarily 
from Nunc while those used for endothelial cell culture are from Costar. For cell freezing, 
a freeze mix comprising of 10% Dimethyl Sulphoxide (Sigma-Alrich) and 90% FBS 





2.2 MSC culture 
2.2.1 MSC isolation and culture 
Human fetal MSCs were obtained by flushing the femurs of terminated fetuses 
from consented donors. The distal epiphyses of the femurs were first removed with a 
scalpel. Next, a 20ml syringe attached with 18G syringe needle was used to flush the 
bone marrow out using 10-15ml of complete DMEM media. The total marrow 
suspension was then filtered through a 70μm cell strainer (Falcon; BD Bioscience) and 
centrifuged at 350 x g for 8 minutes at 4
o
C. Recovered cells were cultured in complete 
media on 100mm culture dishes at 37
o
C in a standard CO2 incubator. Culture medium 
was changed after 24 hours to remove all non-adherent cells. Adherent cells were allowed 
to grow for the next 3-4 days without any change of medium. Upon observing the growth 
of MSC clusters, the culture medium was changed every 2-3 days. At this point, isolated 
MSC culture was labeled as passage 0 cells (P0). When the P0 MSC reached 70% 
confluence, they were washed trice with HBSS before being dislodged with 0.005% 
trypsin. The trypsin was neutralized with DMEM wash buffer and centrifuged at 350 x g 
for 8 minutes at 4
o
C. After centrifugation, the supernatant was discarded and the tube was 
gently flicked to loosen the cell pellet. Next, the cell pellet was re-suspended with 
complete medium and re-plated at a density of 2800 cells/cm
2 
in 150mm culture dishes as 
passage 1 cells (P1). Retro-viral GFP transfected MSC (Provided by Dr Jerry Chan, O&G 
department NUH), were also cultured and passaged as described above. MSC isolation 
protocol was adapted and modified from the original work of Campagnoli et al., 2001 
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while MSC culture protocol was adapted and modified from the original work of Guillot 
et al., 2006. 
 
2.2.2 MSC freezing and thawing 
Cultured MSC at 70% confluence were washed trice with HBSS before 
dislodging with 0.005% trypsin and washed as described in subsection 2.2.1. Next, the 
cell pellet was re-suspended with freeze mix at a concentration of 4 x 10
5
 cells/ml and 
aliquoted in 2 ml cryovials. The cryovials were wrapped with paper towel before being 
placed in a -70
o
C freezer for 24 hours. Subsequently, the paper towel was removed and 
the frozen tube was placed in a liquid nitrogen tank for long term storage. 
 For cell thawing, the frozen cryovial was warmed in a 37
o
C water bath until the 
content was almost melted. 10 ml of DMEM wash buffer was used to dilute the DMSO in 
the freeze mix. The cell suspension was centrifuged at 350 x g for 8 minutes at 4
o
C with 
the supernatant discarded. The cell pellet was flicked to loosen the cells before 
resuspension with 7 ml of complete DMEM medium and plated down in a 100mm 
culture dish. Culture media was changed every 2-3 days. When the culture reached 70% 
confluence, it would be further expanded to generate the required cell numbers for 
subsequent experiments. 
 
2.2.3 Osteogenic differentiation 
Fetal MSC that has are fully confluent were used for osteogenic differentiation. 
Cells at the third, sixth and ninth passages were cultured in complete DMEM medium 
supplemented with 1mM dexamethasone (Sigma-Aldrich), 0.1M ascorbic acid (Sigma-
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Aldrich) and 1M glycerol phosphate (Sigma-Aldrich). Control cells were grown in 
complete culture medium with no additional supplements. Cells were cultured in their 
respective media for 2 weeks and culture media for the cells was replaced every 2-3 days. 
After 2 weeks of culture, cells were washed twice with PBS (1stBase) before being fixed 
in 4% formaldehyde for 10 minutes. Next, the cells were washed again with dH20 prior to 
staining with either Alizarin Red (Sigma-Alrich) stain or Von Kossa stains (1% AgNO3 
solution) which detect calcium and phosphate deposits respectively. Briefly, the cells 
were incubated with the stains for 5-10 minutes at room temperature. At the end of the 
incubation, the stains were aspirated and the cells were washed with dH20 for at least 4-5 
times. Pictures of stained cells were captured using a camera (JVC; TK-C921EG) 
mounted on an inverted microscope (Olympus; IX51) equipped with a 10X objective lens. 
Protocols for osteogenic differentiation and staining were adapted and modified from the 
original works of Campagnoli et al., 2001. 
 
2.2.4 MSC activation 
For cell activation, culture medium was aspirated and cells were washed once 
with HBSS. The cells were subsequently incubated with complete medium containing 
either 1ng/ml or 10ng/ml TNF-α for 24 hours at 37oC in a standard CO2 incubator. Prior 
to use, MSC were dislodged as described in subsection 2.2.1 and resuspended in serum-




2.3 HUVEC culture 
2.3.1 Preparation of gelatin coated dishes for HUVEC  
The 0.1% gelatin stock solution was first prepared by dissolving pre-warmed 
0.5% gelatin (Sigma-Alrich) in dH2O (1:5 ratio). The coating of the dishes was done in 
the sterile environment of a tissue culture hood. 2-3ml of 0.1% gelatin solution was used 
to cover the entire surface of the culture dish and was left in the dish for approximately 1-
2 minutes before being aspirated. Subsequently, a second coat of gelatin was applied in 
the same manner. The coated culture dishes were left in the culture hood to dry for 
approximately 2 hours. After drying, the lids of the culture dishes were taped and the 
dishes were stored for future use. 
 
2.3.2 HUVEC isolation and culture 
The umbilical cord vein was first cannulated at both ends with two-way stopcocks. 
The vein was flushed with HBSS (Sigma-Alrich) using a syringe attached to one of the 
stopcocks. Next, the vein was filled with 1mg/ml of collagenase (1ml for every 2cm of 
umbilical cord), the stopcocks locked at both ends and the whole assembly placed in a 
clean jar. The jar was then placed in a 37
o
C waterbath for 8 minutes. Next, the umbilical 
cord was massaged for 1-2 minutes before flushing the vein for 10-15 times using a 20ml 
syringe filled with HBSS. The content of the collagenase digested vein was collected and 
centrifuged at 350 x g for 8 minutes at 4
o
C. After centrifugation, the supernatant was 
discarded and the tube was gently flicked to loosen the cell pellet. The cells were 
subsequently resuspended in plating media comprising of M199 (Gibco) medium 
supplemented with 20% FBS (Gibco), 25mM HEPES (Gibco), 100 U/ml Penicillin, 100 
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μg/ml Streptomycin (Gibco) and 1% v/v NaHCO3 (Gibco) and 1% v/v L-glutamine 
(Gibco) and seeded on 100mm gelatin coated culture dishes. The cells were incubated in 
a CO2 incubator allowing cells to adhere. After 24 hours, non adherent cells were 
aspirated off and the dish was gently washed with HBSS. Lastly, the cells were cultured 
in complete EGM-2 media supplemented with 10% FBS. On reaching confluence, the 
HUVEC monolayer was washed twice with HBSS before being dislodged with 0.02% 
trypsin. The trypsin was neutralized with M199 wash buffer and centrifuged at 350 x g 
for 8 minutes at 4
o
C. After centrifugation, the supernatant was discarded and the tube was 
gently flicked to loosen the cell pellet. Next, the cell pellet was re-suspended with 
complete EGM-2 media and re-plated in 100mm gelatin-coated culture dishes with a split 
ratio of 1:3. For experiments, HUVEC up to passage 6 were used. Protocols for HUVEC 
isolation, culture and plating on glass coverslips were adapted and modified from the 
original works of Lim et al., 1998. 
 
2.3.3 HUVEC plating on glass coverslips 
Glass coverslips was placed in six-well plates (Cellstar) and wells were filled with 
1-2ml of 70% ethanol for at least 1 minute to disinfect the coverslips. Subsequently, the 
ethanol was aspirated and the coverslips were washed twice with 2 ml of HBSS to 
remove excess ethanol. After the final wash, 1.5ml of HBSS containing 0.05 mg/ml of 
Matrigel
TM
 was placed in each well. The setup was then incubated for at least 5 hours at 
37
o
C in a standard CO2 incubator for the Matrigel
TM
 to polymerize. After incubation, 
trypsinized HUVEC were plated at a density of 0.25 x 10
6
/ coverslip and cultured for 4 
days under standard culture conditions. Twenty four hours prior to the experiment, the 
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HUVEC monolayers were activated with 30ng/ml of TNF-α diluted in a mixture of 
plating medium (defined in subsection 2.3.2) and complete EGM-2 medium in a 1:1 ratio. 
 
2.4 Human leukocyte isolation from fresh blood 
Buffy coat packs obtained from blood donors was used for monocyte isolation. 
The buffy coat was first diluted with HBSS (1:7 ratio) and thoroughly mixed by inversion. 
The mixture was carefully layered over Histopaque (Sigma-Alrich) and centrifuged at 
450 x g for 30min at 22
o
C. The peripheral blood mononuclear cell (PBMC) layer was 
removed with a P1000 pipette, resuspended in complete RPMI-1640 medium comprising 
of RPMI-1640 medium (Gibco) supplemented with 10% FBS (Gibco) and 1X L-
glutamine (Gibco). Total PBMC were enumerated via tryphan blue exclusion method. 
Monocytes were subsequently isolated from the PBMC using CD14 isolation kit 
(Miltenyi Biotec) according to manufacturer specifications. After isolation, the 
monocytes were washed and resuspended in complete RPMI-1640 medium at a 
concentration of 1 x 10
6
 cells/ml. The number of monocytes obtained is usually 8-12% of 
the initial number of PBMC used for the isolation process. 
 Venous blood obtained from donors was used for neutrophil isolation (Nauseef, 
2007). The blood was first diluted 1:1 with dextran-EDTA (4% Dextran and 20nM 




) and mixed thoroughly by inversion (5-10 
times). Subsequently, the mixture was left to stand at room temperature for 20 minutes to 
allow the erythrocytes to sediment. The leukocyte rich plasma was then transferred to a 
50ml tube and centrifuged at 350 x g for 8 minutes at 4
o
C. After centrifugation, the 
supernatant was discarded and the pellet resuspended in 1ml of cold ddH20 for exactly 1 
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minute to lyse remaining erythrocytes. To restore tonicity of the suspension, 9ml of 
complete RPMI-1640 media was added. Next, the suspension was carefully layered over 
Histopaque (Sigma-Alrich) and centrifuged at 450 x g for 30min at 22
o
C to separate 
neutrophils from PBMC. After discarding the supernatant, the neutrophil-rich pellet was 
resuspended in complete RPMI-1640 medium at a concentration of 1 x 10
6
 cells/ml. 
Neutrophil yield was subsequently enumerated with tryphan blue exclusion method using 
a hemocytometer. The purity of the neutrophils used in experiments is above 95% using 





2.5 Flow cytometry analysis 
Cells were dislodged as described in subsection 2.2.1. For the detection of 
trypsin-sensitive proteins, trypsin was replaced with Cell Dissociation Solution (Sigma-
Alrich) as a dislodging agent. After centrifugation, cells were resuspended with DMEM 
wash buffer at a concentration of 2-5 x 10
6
 cells/ml. Subsequently, the cell suspension 
was aliquoted into FACS tubes in 100μl aliquots. Cells were then incubated with 
unconjugated monoclonal antibodies (mAb) for 30 minutes at 4
o
C. The source and 
concentration of the antibodies used in the study are listed in Table 2.1. Corresponding 
isotype mouse antibodies were used as negative controls. Cells were subsequently 
washed with 1ml of DMEM wash buffer and centrifuged at 350 x g for 8 minutes. The 
supernatant was discarded and the cells were incubated with PE or FITC-conjugated goat 
anti-mouse secondary antibodies for 30 minutes at 4
o
C. Next, the cells were washed 
twice as described above, once with DMEM wash buffer followed by PBS. Lastly, the 
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cells were fixed in 350μl of 0.4% formaldehyde in PBS and stored at 4oC in the dark 
prior to data acquisition. Data was acquired on a BD FACScalibur (Becton Dickinson) 









Isotype controls     
Mouse IgG1 




 – PE 
conjugated 
0.1mg/ml 1:100 1µg/ml Caltag 
Rat Ig 3mg/ml 1:5000 0.6µg/ml Caltag 
Integrins     
CD49a (α1) 1mg/ml 1:200 5µg/ml Chemicon 
CD49b (α2) 1mg/ml 1:200 5µg/ml Chemicon 
CD49c (α3) 1mg/ml 1:200 5µg/ml Chemicon 
CD49d (α4) 0.2mg/ml 1:50 4µg/ml AbD Serotec 
CD49e (α5) 1mg/ml 1:200 5µg/ml Chemicon 
CD49f (α6) 1mg/ml 1:200 5µg/ml Chemicon 
CD51 (αV) 1mg/ml 1:200 5µg/ml Chemicon 
CD11a (αL) 0.1mg/ml 1:50 2µg/ml BD Pharmingen 
CD29 (β1) 0.2mg/ml 1:50 4µg/ml Immunotech 
CD18 (β2) 0.5mg/ml 1:50 10µg/ml Biolegend 
CD61 (β3) 0.5mg/ml 1:100 5µg/ml BD Pharmingen 
CD104 (β4) 1mg/ml 1:200 5µg/ml Chemicon 
Integrin β5 0.5mg/ml 1:100 5µg/ml eBioscience 
HUTS21–PE conjugated N.D 1:5 N.D BD Pharmingen 
Other adhesion molecules     
CD44 62.5µg/ml 1:100 0.625µg/ml BD Pharmingen 
CLA–PE conjugated N.D 1:10 N.D Miltenyi Biotec 
CD62L 0.2mg/ml 1:50 4µg/ml Caltag 
E1/6 (VCAM-1) C.S 1:5 N.D - 
Hu5/3 (ICAM-1) C.S 1:5 N.D - 
CD162 (PSGL-1) 0.5mg/ml 1:50 10µg/ml BD Pharmingen 
Receptors     
CD140a–PE conjugated  
(PDGFRα) 
N.D 1:5 N.D Biolegend 
CD140b (PDGFR β) 0.5mg/ml 1:50 10µg/ml Biolegend 
CXCR4 0.1mg/ml 1:50 2µg/ml R&D 
CCR7 0.5mg/ml 1:50 10µg/ml BD Pharmingen 
Surface markers     
FAP 0.1mg/ml 1:50 2µg/ml Santa Cruz 
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W6/32 (MHC class I) C.S 1:5 N.D - 
Secondary Antibody     
Goat anti-mouse IgG-PE 
conjugated 










Table 2.1 Concentration of antibodies used for FACS 
The table shows the list of antibodies and their sources. The dilution factor used, the 
stock and final working concentration are shown as well. The hybridomas for antibodies 
against ICAM-1 (clone Hu5/3), VCAM-1 (clone E1/6) and MHC class 1 (W6/32) are 
gifts from the Vascular Research Division, Department of Pathology, Brigham and 
Women’s Hospital, USA. (N.D denotes Not Determined; C.S denotes Culture 
Supernatant) 
 
2.6 Cell migration assay 
Cells were dislodged as described in subsection 2.2.1 and resuspended in serum-
free DMEM. The transwells used for the assay have 5μm pore size (costar) and were pre-
coated with 0.1% gelatin (Sigma-Alrich). The upper chamber of the gelatin-coated 
transwells was seeded with 2 x 10
5
 cells. Next, the transwells were placed in 24-well 
plates (Costar) filled with serum-free DMEM medium supplemented with soluble 
mediators. Test wells filled with only serum-free DMEM medium were used as negative 
controls. The concentration and source of the soluble mediators added to the bottom 
chamber of the transwells are listed in Table 2.2. Experimental setup was incubated for 5 
hours at 37
o
C in an incubator. 
 After 5 hours, transwells were washed with cold PBS and the upper surface of the 
insert carefully cleaned using a cotton bud. Transmigrated cells on the lower surface of 
the insert were fixed in cold methanol for 15 minutes and air-dried for 1 hour. 
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Subsequently, the membrane was stained using Giemsa (diluted 1:20 using Sorensen’s 
buffer) stain for 30 minutes at room temperature. The stained inserts were carefully 
removed by a scalpel and mounted on microscope slides. 
 The images of twenty one fields were taken for each transwell insert at 10X 
magnification adhering to a map template (Figure 2.1) and the number of transmigrated 










Growth factor     
IGF-1 0.1mg/ml 1:350 350ng/ml Peprotech 
b-FGF 0.1mg/ml 1:1000 100ng/ml Peprotech 
PDGF-AB 0.1mg/ml 1:10000 10ng/ml Peprotech 
TGF-β 0.1mg/ml 1:1000 100ng/ml Peprotech 
VEGF 0.1mg/ml 1:1000 100ng/ml Peprotech 
Chemokines     
SDF-1 α 0.1mg/ml 1:350 350ng/ml Peprotech 
Cytokine     
TNF α 0.1mg/ml 1:10000 10ng/ml eBioscience 
Lipid mediators     
LTB4 297μM 1:1000 350nM Cayman 
LXA4 297μM 1:1000 350nM Cayman 
 
Table 2.2 Concentration of mediators used for transwell experiment 
The table shows the list of mediators and their sources. The dilution factor used, the stock 


















Figure 2.1 Positions map of fields taken on a transwell insert 
The grey rectangles represent the relative positions where the twenty-one images were 
taken. Each grey rectangle depicts a single microscope field under 10X objective. Black 
lines symbolize a distance of three 10X objective fields while blue lines symbolize one 
and a half fields. 
 
2.7 Parallel plate flow chamber assay 
GFP-labeled MSC were dislodged as described in subsection 2.2.1 within 1-2 
hours prior to the assay. Cells were subsequently aliquoted at a concentration of 1 x 
10
6
/ml in complete DMEM medium. Likewise, freshly isolated monocytes or neutrophils 
were resuspended at a concentration of 1 x 10
6
/ml in complete RPMI-1640 medium 
containing 10% FBS and 1X L-glutamine.  
 A 10-cm rectangular parallel plate flow chamber containing a 5-mm wide and 
0.01-inch high channel was used for the in vitro flow experiments. In all experiments, the 
flow chamber was pre-heated up to 37
o
C and DMEM wash medium pre-warmed to 37
o
C 
was used as a flow buffer. Using a syringe pump (Harvard Apparatus), the cell 
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suspension was drawn through the flow chamber at different flow rates. The wall shear 
stress (, expressed in dynes/cm2), which is dependent on the flow rate and viscosity of 
the cell suspension can be defined by the equation: 
                                                 (dyne/cm
2
) = 6µQ/ bh2, 
Where µ is the viscosity of the fluid expressed in poise; Q is the flow rate of the fluid 
expressed in centimeters per second; b is the width of the chamber and h is the distance 
between the plates, both expressed in centimeters (Bacabac et al., 2005).  
 The TNFα-activated HUVEC monolayer on glass coverslip (as described in 
subsection 2.3.3) was mounted on the flow chamber. Cells were perfused through the 
flow chamber at a concentration of 1 x 10
6
 cells/ml. Prewarmed MSC, monocytes or 
neutrophils were first perfused over the HUVEC monolayer at a sheer stress of 
0.5dynes/cm
2
 for 2 minutes. Then, the live-time cell-cell interactions in 10 random fields 
were video recorded using a CCD camera (Sony; SVT-N24P) mounted on an inverted 
microscope (Nikon; Eclipse TE2000-U) equipped with a 20X objective (Nikon).  
 For blocking experiments, GFP- labeled hfMSC were pre-incubated with 20μg/ml 
of mouse anti-human monoclonal antibodies (anti-alpha 4 integrin: clone HP2/1 from 
AbD Serotec; anti-beta 1 integrin: clone Lia1/2 from Immunotech) for 15 minutes at 
room temperature prior to perfusion across the HUVEC monolayer. A matching mouse 
immunoglobulin (Invitrogen) was used as an isotype control. 
 
2.8 Wound healing assay 
HfMSC of passage 4-5 were seeded in 24-well plates (Costar) at a concentration 
of 2 x 10
4
 cells/well and cultured for 2-3 days. Once the cells reached 50% confluence, 
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twelve of the wells were activated with either 10ng/ml or 1ng/ml of TNFα for 24hrs. On 
reaching 80% confluency, the well was carefully scratched from the top to bottom with a 
P200 pipette tip. Next, the wells were washed 4 times with HBSS (Sigma-Alrich) to 
remove any cell clumps and debris formed during the scratching. After washing, the 
wells were replaced with serum free DMEM in control wells. In test wells, the serum free 
media was supplemented with either 10 ng/ml of TNF-α (eBioscience), 10 ng/ml of 
PDGF-AB (Peprotech) or a 1:1 mixture of both. Four fields along the length of the 
wound were taken under 4X objective according to a specific map (Figure 2.2). This was 
to allow the same region of the wound to be assessed at the end of the assay 10 hours 
later. The width of the wound in each field was the average of four different 
measurements of the distance between opposing sides of the wound in a field. 
Subsequently, the percentage closure of the wound was determined by dividing the 
difference of the wound width before and after the assay by initial wound width. 
Protocols for the wound healing assay was adapted and modified from Nature Protocols 
(Liang et al., 2007).  
 
2.9 Statistical Analysis 
For statistical analysis of experimental results, student’s t-test was utilized to 
determine statistical significance which was set at 95%. The software used for the 














Figure 2.2 Positions map of fields taken during a wound healing assay 
The circle represents a well on a 24-well plate where approximately 19 4X objective 
fields can be taken from the top to the bottom of the well. Each black rectangle represents 
three 4X objective fields while all other rectangles each represent one 4X objective field. 
The four grey rectangles represent the fields that were taken during the experiments. 
Fields were taken according to this map to ensure that the same fields (grey rectangles) 











3.1 Characterization of hfMSC 
 To date, most studies on MSC recruitment was done on cells from adult donors 
(Wobus et al., 2006). Therefore, MSC from adult sources is well studied unlike those 
from fetal sources. Since our study involves the use the fetal MSC, there is a need for 
characterization prior to their use in subsequent experiments. Work was done to 
investigate the expression of adhesion molecules, growth factor and chemokine receptors 
as well as the osteogenic potential of hfMSC.  
 
3.1.1 HfMSC exhibits osteogenic potential in vitro 
 First, we assessed the osteogenic potential of our hfMSC using alizarin red to 
stain the differentiated cells for calcium deposits. Seven out of the eight hfMSC lines 
tested were able to differentiate into osteocyte-like cells which deposited calcium (Figure 
3.1 Panels A-C). The one line that was unable to differentiate was excluded from future 
experiments. Subsequently, three lines were randomly chosen to test the effects of 
increasing time in culture on the differentiation potential of the cells. As shown in Figure 
3.1 panels D-G, the hfMSC were able to differentiate from passage three through passage 
nine. Across the various passages, there were no obvious differences in the extent of 
differentiation as shown by the alizarin red staining intensity. In addition, the amount of 
time required for the cells to undergo differentiation was similar across the different 
passages.  
 Interestingly, hfMSC from one particular donor was able to differentiate into 
adipocytes despite being cultured in osteogenic media and this was confirmed by with Oil 
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Red O staining (Data not shown). However, this observation was only seen in one donor 
line and was probably due to spontaneous differentiation under uncontrolled conditions. 
















Figure 3.1 hfMSC undergo osteogenic differentiation  
HfMSC were able to differentiate into phosphate and calcium depositing cells as shown 
by (A) Von Kossa staining and (B) Alizarin Red staining respectively as compared to (C) 
undifferentiated cells which were unable to deposit phosphate or calcium. HfMSC from 
(D) Passage 3, (E) Passage 6, (F) Passage 9 were able to undergo osteogenic 
differentiation shown by the alizarin red staining as compared to (G) undifferentiated 
cells which were unable to take up the stain. Photos were taken with a digital camera and 
are representative pictures from six independent experiments in the upper panel and three 
independent experiments in the lower panel. 






3.1.2 Surface markers expressed by hfMSC 
 To date, there is no single surface marker which can be used to identify MSC 
from other cell-types. Therefore, most researchers employ a panel of both positive and 
negative markers to differentiate MSC from other cells native to the bone marrow 
(Wobus et al., 2006). Classically, MSC are positive for stem cell markers such as Stro-1, 
Thy-1, Sca-1 and CD146 while being negative for hematopoietic markers such as CD4, 
CD8, CD14 and CD19. Therefore, we wish to find out if hfMSC was positive for some 
other unique markers that were documented to be expressed by adult MSC. 
 Bae et al carried out a study which utilized the transcriptome and proteome of 
MSC to identify potential surface markers to differentiate them from other cells within 
the bone marrow  (Bae et al., 2008). A candidate protein on adult MSC which could serve 
this function was the fibroblast activation protein (FAP). The study showed that FAP was 
only expressed on bone marrow MSC but not on resting or activated immune cells found 
within the bone marrow. Using FACS, we stained two hfMSC lines for FAP expression 
and one line across increasing passage numbers to detect possible changes in expression 
levels. 
 More than 60% of total hfMSC express FAP on their surface and the percentage 
of positive cells increased at passage 6 and passage 9 (Figure 3.2, Panel A). As it has 
been documented that FAP expression in chondrocytes was increased following a pro-
inflammatory stimulus (Milner et al., 2006), we tried to find out if treatment with pro-
inflammatory cytokines such as TNFα will affect its expression in MSC.  From the data, 
FAP expression did not change with treatment with TNFα, suggesting that TNFα 
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signaling may not affect the expression of FAP (Figure 3.2, Panel B). FAP is reported to 
be a marker expressed by fibroblasts during wound healing (Gao et al., 2009). In addition, 
FAP was also found to be a tumour suppressor protein in mouse melanoma cells 
(Ramirez-Montagut et al., 2004). But it is not known if TNFα signaling in MSC can 
affect the expression or functions of FAP. From the data, it was observed that a high 
basal expression of FAP was found on the studied donor line (Figure 3.2, Panel B). 
Therefore, it would be worthwhile to repeat the experiment using younger passage cells 
and also other donor lines in order to determine if this observation was due to a line 
variation or a passage effect. Thus, with the exception of identifying MSC from other 
cells within the bone marrow, more work is required to determine if FAP could be used 











Figure 3.2 hfMSC express moderate to high levels of FAP 
(A) Histograms show the expression levels of FAP on hfMSC with increasing passage 


























(B) Compared to untreated cells, TNFα treatment does not influence the expression of 
FAP on hfMSC. Purple histograms indicate the expression level of FAP while the red 
lines indicate the fluorescence signals from a non-binding isotype control antibody. 
Numbers in figures represent the percentage of cells which stained positive for FAP 
(Figures are representative of two independent experiments using two donor lines for 
panel A and one donor line for panel B) 
 
3.1.3 HfMSC expresses a range of integrins and other adhesion molecules 
 MSC recruitment is believed to be similar to that of leukocyte recruitment which 
involves the interplay between the adhesion molecules expressed on endothelial cells and 
leukocytes. As most recruitment studies conducted on human MSC to date were done on 
adult cells (Ruster et al., 2006), it will be important to find out whether the adhesion 
molecules expressed on hfMSC are comparable to those reported for haMSC. Therefore, 
we used FACS to stain for integrins and other adhesion molecules on three of our hfMSC 
lines. 
 Compared to a non-binding mouse antibody which served as our negative control, 
most of the adhesion molecules expressed showed consistent staining across the different 
hfMSC lines. Figure 3.3 (solid purple histograms) shows the FACS analysis for the 
surface adhesion molecules expressed on a representative hfMSC line. HfMSC was 
shown to express high levels of surface α3, α5, α6, αV, β1, β5 integrin and low levels of 
α4 integrin. Certain amount of variability was observed in the staining for α1, α2 and β3 
integrins which ranged from moderate to high expression across the various hfMSC lines 
tested (Figure 3.3, Panel A). Next, the cells were found to be negative for leukocytes-
specific adhesion molecules such as αL, β2 integrins, L-selectin, CD15, cutaneous 
lymphocyte-associated antigen (CLA) and P-Selectin glycoprotein ligand-1 (PSGL-1) 
(Figure 3.3, Panel B). This suggests that the mechanism which MSC utilize to home to 
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target sites may potentially be different from that of leukocytes in the context of the 
adhesion molecules used. Lastly, hfMSC also express low levels of ICAM-1 and VCAM-
1 which is consistent with their functions as stromal cells within the bone marrow (Figure 
3.3, Panel C). 
 In studies done on adult MSC (haMSC), similar expression levels of integrin 
molecules to those on our hfMSC were also found (Majumdar et al., 2003). In addition, 
adult MSC also lacks expression of leukocyte-specific adhesion molecules as mentioned 
above (Majumdar et al., 2003; Ruster et al., 2006). Thus, this suggests that the expression 
of adhesion molecules found on hfMSC is consistent with those found on haMSC. 
 
3.2 Changes in receptors and adhesion molecules expression after TNFα treatment 
 TNFα has been documented to up-regulate adhesion molecules on vascular 
endothelial cells under inflammatory conditions (Modur et al., 1996). In addition, TNFα 
has also been shown to augment MSC migration under both in vitro and in vivo 
conditions (Kim et al., 2009; Ponte et al., 2007). Therefore, we endeavored to investigate 
whether TNFα signaling would be able to regulate the expression of adhesion molecules 
or receptors on hfMSC. Surface expression profile of adhesion molecules, chemokine 
receptors and growth factor receptors will be compared between TNFα-treated and 
untreated control hfMSC. In addition, the osteogenic potential of hfMSC after TNFα 




3.2.1 Integrin expression on hfMSC were not affected by TNFα treatment 
 We examined the expression of integrin molecules comparing between TNFα 
treated and untreated hfMSC in three different hfMSC lines. In Figure 3.3, solid purple 
histograms indicate the staining intensity of untreated cells while red lines indicate 
staining intensity of TNFα-treated cells. A dotted vertical line is created based on 
fluorescence intensity from a matched isotype control and superimposed on all 
histograms allowing for comparison. TNFα did not induce any change in the surface 
expression of most of the adhesion molecules that were expressed by hfMSC compared 
to untreated conditions (Figure 3.3, Panel A). The only exceptions to this observation are 
alpha 2 integrin and beta 3 integrin which showed increased expression after 24 hours of 
TNFα stimulation. Lastly, surface adhesion molecules found on leukocytes such as αL, 
β2 intergrin (LFA-1), L-selectin, CD15, CLA and PSGL-1 which were undetected on 
untreated hfMSC, did not change in surface expression following TNFα exposure (Figure 
3.3, Panel B).  
  
3.2.2 ICAM-1 and VCAM-1 surface expression were up-regulated on hfMSC 
treated with TNFα 
 Interestingly, TNFα treatment was able to up-regulate the surface expression of 
both ICAM-1 and VCAM-1 (Figure 3.3, Panel C). Therefore, we further examined the 
effects of TNFα on the expression of these adhesion molecules by varying the 
concentration and duration of exposure to the cytokine. 
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 Figure 3.4 shows the surface expression histograms of ICAM-1 and VCAM-1 
comparing hfMSC which have been exposed to 10ng/ml TNFα for 5 hours, 24 hours and 
48 hours against untreated cells. Under unstimulated conditions, hfMSC express low 
surface levels of both ICAM-1 and VCAM-1. However, expression levels for both 
adhesion molecules were increased after 24 hrs of exposure to 10ng/ml TNFα. ICAM-1 
expression showed a time dependent increase which peaked at 24hrs. This increased 
expression of ICAM-1 was shown to be maintained up to 48 hours. On the other hand, 
VCAM-1 expression peaked after 5 hours of TNFα exposure and decreased subsequently 
after 24 hours and 48 hours of TNFα treatment. However, there was still a residual 
expression of VCAM-1 after 48 hours of TNFα treatment where more than 50% of the 
cells still expressed the adhesion molecule. This trend was similar to that observed in a 
study which investigated the effects of TNFα concentration and exposure duration on the 
adhesion molecules expressed on HUVEC (Chen et al., 2001). The data suggests that 
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Figure 3.3 FACS analysis of hfMSC surface adhesion molecules expression 
following TNFα stimulation 
Histograms show the expression levels of various surface adhesion molecules expressed 
by hfMSC before and after TNFα treatment. Purple histograms indicate the expression 
level of untreated cells while the red lines indicate the expression level of TNFα treated 
cells. Dotted line indicates background staining intensity based on the isotype control. 
Expression of (A) adhesion molecules on hfMSC which were unaffected by TNFα 
treatment (Numbers in figures are indicative of the change in cell positivity following 24 
hours of TNFα stimulation); (B) adhesion molecules that were not detected on hfMSC (C) 
Adhesion molecules on hfMSC which were up-regulated after TNFα treatment (Figures 
are representative of three independent experiments using three different donor lines) 
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Figure 3.4 TNFα exposure increases ICAM-1 and VCAM-1 surface expression on 
hfMSC 
Left and right panels show the surface expression of ICAM-1 and VCAM-1 respectively. 
The purple histogram indicates the fluorescence intensity detected in the non-binding 
isotype control. The green line indicates the ICAM-1 and VCAM-1 expression on 
unstimulated hfMSC. The pink, blue and orange lines indicate the ICAM-1 and VCAM-1 
surface of expression on hfMSC that were treated with TNFα for 5, 24 and 48 hours 
respectively. (Figures are representative of two independent experiments using one donor 
line) 
 
3.2.3 TNFα treatment of hfMSC results in down-regulation of surface PDGFRα 
In addition to adhesion molecules found on the cell surface, receptors for chemokines or 
growth factors are required for cell trafficking to target sites. Using FACS analysis, we 
ICAM-1 VCAM-1 
IgG isotype 
48hrs TNFα (10ng/ml) 
Untreated 
5hrs TNFα (10ng/ml) 




stained for a panel of four receptors: PDGFRα, PDGFRβ, CXCR4 and CCR7 at both the 
intracellular and extracellular level in three of our hfMSC lines. 
 Figure 3.5 shows the expression of various chemokine and growth factor 
receptors expressed on unstimulated hfMSC. HfMSC stained positive for surface 
PDGFRα with minimal number of cells expressing surface PDGFRβ (Figure 3.5, Panel 
A). Donor variability seemed to exist for PDGFRα surface expression as only two out of 
the three lines tested express surface PDGFRα. We tried to link the presence of surface 
PDGFRα with the gestation period of the fetus but there were no obvious associations. 
Therefore, whether an hfMSC line expressed surface PDGFRα was probably due to some 
unknown factors and not with the age of the fetus. On the other hand, both PDGFRα and 
PDGFRβ were found within the cell in all four lines, albeit in moderate amount (Figure 
3.5, Panel A). As for chemokine receptors, surface expression of both CXCR4 and CCR7 
were found to be low (approximately 10% of total cells) across the three hfMSC lines 
tested (Figure 3.5, Panel B and C). However, most of the cells from the three lines tested 
were positive for both chemokine receptors at the intracellular levels. Consistent with 
other studies, the expression levels of these tested receptors on hfMSC was comparable to 
those found on adult MSC (Ball et al., 2007; Sordi et al., 2005). 
 Next, we wished to find out whether exposure to TNFα will up-regulate both total 
(intracellular) and surface expression of these receptors on hfMSC. After 24 hours of 
TNFα stimulation, PDGFRα surface expression was down-regulated by about 36% while 
surface expression of PDGFRβ, CXCR4 and CCR7 were unchanged (Table 3.1, Panel A). 
TNFα treatment seemed to reduce the intracellular expression of all four receptors (Table 
3.1, Panel B). This probably suggests that TNFα signaling may decrease the production 
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of these receptors. Studies have shown that TNFα reduces the surface expression of 
PDGFRα on osteoblastic cells (Kose et al., 1996) and CXCR4 on astrocytes (Han et al., 
2001) by decreasing mRNA levels. Thus, the observed decrease in surface PDGFRα may 






























































Figure 3.5 FACS analysis of PDGFRαβ, CXCR4 and CCR7 expression in 
unstimulated hfMSC 
The left panel shows the extracellular expression while the right panel shows intracellular 
expression of the receptor of interest. (A) PDGFRα and PDGFRβ expression on hfMSC. 
Vertical and horizontal axis indicates log fluorescence intensity of PDGFRα and 
PDGFRβ respectively. Grid for quadrants was drawn based on the signals from mouse 
IgG isotype control (Left panel). (B) CXCR4 and CCR7 expression on hfMSC. Purple 
histograms indicate the staining intensity of the receptors while and red lines indicate the 
staining intensity of a non-binding antibody isotype control. The M1 gate was set based 
on the fluorescence signals from the negative control. Vertical axis indicates the number 
of events/cells and horizontal axis indicates log fluorescence intensity. Numbers in the 
figures indicate the percentages of positively stained cells. (Figures are representative of 


















































Table 3.1 Changes in PDGFRα, PDGFRβ, CXCR4 and CCR7 expression in hfMSC 
following TNFα stimulation 
Expression of various chemokine and growth factor receptors in hfMSC before and after 
TNFα stimulation. (A) – Extracellular expression, (B) – Intracellular expression; 
Numbers in the figures indicate the percentages of positively stained cells. (Data: mean ± 
s.e.m from three experiments for extracellular PDGFRα, CXCR4 and mean ± s.e.m from 
four experiments for the others. Three different donor lines were used) 
 
3.2.4 TNFα treatment of hfMSC does not affect osteogenic differentiation  
 In our assays, TNFα was shown to increase the surface expression of ICAM-1 and 
VCAM-1 while decreasing PDGFRα surface expression. Following this, we examined 
whether the differentiation potential of these cells was altered by treatment with TNFα.  
 In Figure 3.6, it is observed that TNFα-treated hfMSC can also differentiate into 
osteocytes-like cells as efficiently as untreated cells (Centre and right panel). Both 
control cells and TNFα-treated cells took approximately two weeks to differentiate. As 
shown by the intensity of alizarin red staining, the magnitude of differentiation does not 
vary greatly between control cells and TNFα-treated cells. From this, it can be inferred 















Figure 3.6: Comparison of differentiation potential between untreated and TNFα-
treated cells.  
Left panel: undifferentiated cell; Centre panel: untreated and differentiated cells; Right 
panel: TNFα treated and differentiated cells. Top panel shows the macroscopic view 
while the bottom panel shows the microscopic view of the cells. Photos from the top 
panel were taken using a digital camera and while those of the bottom panel were taken 
using a microscope camera under 10X magnification. (Black bar: 50 microns) 
 
3.3 HfMSC interaction with HUVEC under defined flow conditions 
The recruitment of MSC to injury site would be likely to involve interactions with 
vascular endothelial cells. These interactions would be mediated by adhesion molecules 
expressed on MSC recognizing their counter-receptors found on activated endothelial 
cells. Therefore, we wish to elucidate the key adhesion molecules expressed on hfMSC 
which is responsible for these interactions. Also, we would like to find out whether TNFα 
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treatment of hfMSC would augment this process. Finally, at an inflammatory site, 
leukocytes are also recruited in large numbers and we wish to investigate the possible 
interplay between leukocytes, MSC and the endothelium under defined flow conditions. 
 
3.3.1 HfMSC interacts with HUVEC via α4β1 integrins under defined flow 
conditions  
 To examine the interactions between MSC and endothelial cells, hfMSC was 
perfused over TNFα-activated HUVEC. It was observed that hfMSC interacted with the 
HUVEC in a flow dependent manner where more cells bound at the lower shear rate of 
0.5dynes/cm
2
 (Figure 3.7). Therefore, all subsequent flow chamber assays were done at 
the lowest shear rate.  
 Preliminary data showed that hfMSC utilizes VLA4 to interact with recombinant 
human VCAM-1 (Data not shown). Thus we wished to find out whether hfMSC-HUVEC 
interactions were mediated by these same adhesion molecules. Using function blocking 
antibodies, we tried to elucidate the adhesion molecules on hfMSC that was responsible 
for these interactions. 
 It was observed that blocking alpha 4 integrin significantly blocked the hfMSC 
interactions with HUVEC (Figure 3.8). Although the partner of alpha 4 integrin is beta 1 
integrin (VLA4), blocking of the latter did not result in a substantial block in MSC-
HUVEC interactions. Treatment of hfMSC with non-specific mouse isotype control did 














Figure 3.7: MSC-HUVEC interactions under defined flow conditions. 
HfMSC were perfused over TNFα-activated HUVEC monolayer. The vertical axis 
represents the average number of MSC per mm
2
 interacting with HUVEC while the 
horizontal axis represents the shear rate that the hfMSC were being perfused in. (Data: 
mean ± s.e.m from five experiments using one donor lines) 
 







Figure 3.8 The effects of blocking antibodies against alpha 4 and beta 1 integrins on 






















HfMSC were pre-treated with function-blocking antibodies prior to perfusion over 
HUVEC monolayer. The vertical axis represents the average number of MSC per mm
2
 
interacting with HUVEC while the horizontal axis represents the treatment that MSC 
received prior to being perfused over HUVEC. A two-tailed student’s t-test was 
conducted and * denotes p<0.05 when compared to muIgG. (Data: mean ± s.e.m from 
three experiments using two donor lines) 
  
3.3.2 TNFα inhibits hfMSC interactions with HUVEC under defined flow conditions 
 Upon establishing a baseline interaction between hfMSC and TNFα-activated 
HUVEC, we wished to find out whether pre-treating hfMSC with TNFα can enhance 
MSC-HUVEC interactions. Thus, we repeated the flow chamber assay using hfMSC 
treated with TNFα for 24 hours and TNFα-activated HUVEC. 
 Interestingly, interactions between TNFα-treated hfMSC and HUVEC were 
consistently inhibited (Figure 3.9). We observed a two-fold reduction in the number of 
hfMSC that were able to adhere on the HUVEC monolayer. From the FACS staining 
done on TNFα-treated hfMSC (See Figure 3.3), there was no difference in VLA4 surface 
expression or any of the other integrins expressed on the cells. Therefore, this decrease in 
interaction is not likely to be due to a change in the expression levels of adhesion 
molecules. It has been shown that TNFα treatment of fibroblasts reduces alpha 2 beta 1 
integrins binding to collagen by inhibiting focal adhesion formation (Chou et al., 1996). 
Therefore, it might be possible that TNFα signaling in hfMSC led to a decrease in affinity 





























Figure 3.9 The effects of TNFα pretreatment on MSC-HUVEC interactions under 
defined flow conditions 
(A) Photos taken during the parallel plate flow chamber assay under a 20X objectives. 
Left: Untreated hfMSC (Left) and TNFα-treated hfMSC (Right) being perfused over 
activated HUVEC. (White bar: 30 microns) (B) The effect of TNFα stimulation on the 
average number of hfMSC adhering on HUVEC. The vertical axis represents the average 
number of MSC per mm
2
 interacting with HUVEC while the horizontal axis represents 












these experiments was fixed at 0.5 dynes/mm
2
. (Data: mean ± s.e.m from three 
experiments using two donor lines) 
 
3.3.3 Monocytes rescue TNFα-induced inhibition of hfMSC-HUVEC interaction 
 It was totally unexpected that TNFα pretreatment so efficiently inhibited hfMSC-
HUVEC interactions under defined flow conditions. From our FACS analysis of TNFα 
activated hfMSC, the only adhesion molecules that were up-regulated were ICAM-1 and 
VCAM-1. Hence, we wished to see whether a cell that is capable of interacting with 
ICAM-1 or VCAM-1 will be able to bridge the interactions between hfMSC and HUVEC. 
Therefore, we introduced a third cell type into the system, monocytes isolated from fresh 
human blood. And by using GFP-labelled hfMSC, we would be able to differentiate the 
hfMSC from the monocytes under fluorescence (Figure 3.10, Panel A).  
 When monocytes were introduced into the system, the number of TNFα-treated 
hfMSC interacting with the HUVEC monolayer was comparable to that seen for 
untreated hfMSC (Figure 3.10, Panel B). Most of the adhered hfMSC were found to be 
physically associated with monocytes (Figure 3.10, Panel A), suggesting that they may be 
interacting via some surface adhesion molecules. To find out whether this interaction was 
mediated by VLA4-VCAM-1 or LFA1-ICAM-1, we used another freshly isolated cell 
type, neutrophils.  
 Mature neutrophils are the predominant inflammatory cells that are recruited 
during the early onset of an inflammatory response. As matured neutrophils do not 
express any VLA4 (Kirveskari et al., 2000), by flowing neutrophils together with TNFα-
treated hfMSC would allow us to elucidate the importance of VLA4 in this recruitment 
process. Neutrophils, unlike monocytes, were not able to rescue the TNFα-induced 
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inhibition of MSC-HUVEC interaction. In addition, the presence of neutrophils seemed 
to inhibit the interaction further as the number of adhered hfMSC was even lower 
compared to TNFα-treated hfMSC alone. As neutrophils and monocytes are recruited 
during different phases of the inflammatory cascade (Kaplanski et al., 2003), this may 
suggest an optimum timeframe for MSC administration and recruitment following an 
injury. 
 










































Figure 3.10 Changes in MSC-HUVEC interactions in the presence of fresh human 
monocytes or neutrophils  
(A) Photos taken during the parallel plate flow chamber assay under a 20X objectives. 
Left: TNFα-treated hfMSC and monocytes being perfused together over activated 
HUVEC; Right: TNFα-treated hfMSC and neutrophils were being perfused together over 
activated HUVEC. Red asterisks denote the positions of the GFP-tagged hfMSC. (White 
bar: 30 microns) (B) The number of hfMSC adhering on HUVEC in the presence or 
absence of leukoctyes. The vertical axis represents the average number of MSC per mm
2
 
interacting with HUVEC while the horizontal axis represents the cell type(s) being 
perfused over the HUVEC. Shear rate used in these experiments was fixed at 0.5 
dynes/mm
2
. (Data: mean ± s.e.m from three experiments or four experiments using one 
donor line)  
 
3.4 Response of hfMSC to soluble mediators  
 MSC are widely documented to express receptors for a wide range of chemokines 
and growth factors (Ponte et al., 2007). However, there is still no conclusive evidence to 
date as to which receptor plays a major role in the recruitment and homing of MSC. In 
addition, within the microenvironment of an injury site, there are many different cell 
types secreting various soluble mediators which may affect MSC response and migration.  





investigate which of them could induce a migratory response in hfMSC. After identifying 
a potential soluble mediator, we would find out if TNFα treatment of hfMSC could 
augment the migratory response.  
 
3.4.1 HfMSC responds to IGF-1 and PDGF-AB in an in-vitro transwell system 
 To determine which soluble factors (cytokines, growth factors, chemokines and 
lipid mediators) hfMSC can respond to, an in vitro transwell assay was used. A panel of 
soluble factors was put in the bottom chamber of the transwells and the migratory 
response of the hfMSC was assayed (Figure 3.11, Panel A). A total of three different 
hfMSC lines were tested for their response towards these soluble mediators. 
 Out of the panel of soluble factors tested, hfMSC was observed to respond 
positively only towards IGF-1 and PDGF-AB, with the response towards PDGF-AB 
being greater (Figure 3.11, Panel B). This was of no surprise as we have shown the 
expression of surface PDGFRα and intracellular PDGFRα and PDGFRβ in hfMSC 
(Figure 3.5). Therefore, given the response of hfMSC towards IGF-1, they should also 
express surface receptors for this growth factor (Thomas et al., 1999). SDF-1, the ligand 
for CXCR4 has been implicated in MSC homing to the bone marrow (Shi et al., 2007).  
Studies done by other groups have shown that the presence of intracellular CXCR4 was 
sufficient for MSC to respond chemotactically to SDF-1 (Honczarenko et al., 2006; Ponte 
et al., 2007; Stich et al., 2009). It was interesting to note that hfMSC did not respond 
chemotactically to SDF-1 within our system, (Figure 3.11, Panel B) even though they 
were shown to express intracellular and low levels of surface CXCR4 (Figure 3.5). This 
probably suggests that the existing surface level of CXCR4 was unable to mediate 
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hfMSC chemotaxis towards SDF-1 within our system. On the other hand, it is also 
possible that MSC may need to be exposed to SDF-1 for a certain amount of time for the 
externalization of intracellular receptor store prior to CXCR4 signaling. In fact, hfMSC 
exposed to SDF-1 for 5-10 minutes showed a slight increase in surface CXCR4 signaling 
(Data not shown). 
A 
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Figure 3.11 Response of hfMSC to various soluble mediators in an in vitro transwell 
assay 
(A) Random fields taken from transwell insert under 10X objectives showing the purple 
nucleus of hfMSC stained by Giemsa stain. (White bar: 50 microns) (B) The chemotactic 
effects for various soluble mediators were tested for and a positive response was seen 
only for IGF-1 and PDGF-AB while there was no significant effect for other soluble 
mediators tested. Student t-tested was conducted and * denotes p<0.05 when compared to 
negative (medium) control. (Data: mean ± s.d from one representative experiment) 
 
3.4.2 TNFα stimulation enhances basal migratory response of hfMSC and alters 
their response to PDGF-AB 
 After establishing the migratory response of hfMSC to PDGF-AB and IGF-1, we 
wished to find out whether pre-treatment of hfMSC could enhance these migratory 
responses. We also examined whether different concentrations of TNFα could exert 






 At both the concentrations of TNFα used, hfMSC showed increased basal motility 
even in the absence of PDGF-AB (Figure 3.12, Panel A). Compared to untreated cells, 
TNFα-stimulated cells showed a four-fold increase in migration across the 5μm pore 
membrane into the bottom well. In the presence of PDGF-AB, hfMSC which were 
activated at both TNFα concentrations (1ng/ml and 10ng/ml) also showed increased 
response compared to unstimulated cells. However, cells which were activated with 
1ng/ml of TNFα showed a greater response to PDGF-AB when compared to cells 
activated with 10ng/ml of TNFα (Figure 3.12B, light grey bars). This data suggests that 
the concentration of TNFα used to activate MSC might affect the response of MSC 
towards PDGF-AB. 
 Interestingly, the combination of TNFα together with PDGF-AB at the bottom of 
the transwell had an effect on hfMSC migration which was not observed when only 
TNFα was used in the bottom well. The response of untreated hfMSC to PDGF-AB was 
inhibited in the presence of TNFα (Figure 3.12B, dark grey bars). On the other hand, 
hfMSC which were pre-stimulated with TNFα did not exhibit this inhibition (Figure 
3.12B, grey bars). This may suggest the presence of a desensitization mechanism which 
was activated after pre-treating hfMSC with TNFα, thus protecting the cells from 


























Figure 3.12 Effects of TNFα stimulation on hfMSC migration in transwell system 
The basal migratory response of hfMSC in the absence (A) and presence (B) of PDGF-
AB. * denotes p<0.05 when compared to respective medium control; * denotes p<0.05 
when compared to untreated cells; # denotes p<0.05 when compared to cells exposed to 
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3.4.3 Wound healing assay 
 Although the transwell assay was able to reveal the response of hfMSC towards 
PDGF-AB, it was not sensitive enough to identify whether the response was chemotactic 
or activating in nature. This is because being a three-dimensional assay, the transwell 
allows for medium containing a higher concentration of PDGF-AB in the bottom 
chamber while cells are suspended in medium with no PDGF-AB. This setup exposes the 
MSC to a concentration gradient of PDGF-AB in which they may respond 
chemotactically towards. Therefore, we used the wound healing assay, which is a two-
dimensional assay where cells are exposed to a homogenous medium (no concentration 
gradient of PDGF-AB). In this way, we would be able to study the effects of PDGF-AB 
(and possibly other soluble mediators in future) on the chemokinesis of hfMSC.  
 Similar to the transwell assay, hfMSC was first pretreated with either 1ng/ml or 
10ng/ml of TNFα for 24 hours before being subjected to the wound healing assay. Figure 
3.12 shows the results of the wound healing assay where the percentage difference in the 
width of the wound was plotted against the soluble factor the cells were exposed to 
during the assay. TNFα activated hfMSC (using both 1ng/ml and 10ng/ml of TNFα) 
showed a slightly more active response compared to untreated cells (Figure 3.13, 
comparing dark grey with light grey bars). Additional exposure to soluble factors such as 
TNFα alone and PDGF-AB alone or in combination did not result in any significant 
increase in response from the cells. Together with the transwell results, these data 
suggests that the response of hfMSC to PDGF-AB maybe chemotactic in nature. Thus, 
this supports the hypothesis that PDGF-AB present in wound sites act as a potential 




























Figure 3.13 Response of hfMSC to various soluble mediators in a wound healing 
assay 
Wound healing response hfMSC stimulated with (A) 10ng/ml TNFα and (B) 1ng/ml 
TNFα stimulated hfMSC in the presence of various soluble factors. Vertical axis 
indicates the percentage difference in wound size at T=0 and T=10hrs. Horizontal axis 
indicates the soluble mediator that the cells were exposed to. Concentrations of soluble 
mediators used were kept at 10ng/ml. Combo: TNFα and PDGF-AB being mixed 













































































 Over recent years, mesenchymal stem cells (MSC) have received much attention 
after being shown to be suitable for clinical applications in many regenerative and 
inflammatory diseases (Le-Blanc et al., 2008; Strauer et al., 2003). However, there is a 
need to develop minimally-invasive use of MSC as many pre-clinical studies done in 
mouse models involved on-site administration which requires invasive surgical 
procedures. MSC are currently being used in phase II and III placebo-controlled clinical 
trials for various diseases (Osiris Therapeutics Inc. website: www.osiristx.com), where ex 
vivo expanded MSC were infused systemically into subjects. However, despite the 
promising results seen in trials and pre-clinical studies, the mechanism by which MSC 
home to inflammatory sites largely remains unelucidated. In our study, we aimed to find 
out the probable mechanism(s) utilized by MSC to home to injury sites following 
mobilization from the bone marrow in response to injury in vivo.  
 This is an important study as to date, many published work on the mechanism of 
MSC recruitment has been either repetitive or conflicting. Therefore, more work is 
needed to elucidate the events that regulate the homing of MSC to injury sites. In our 
study we tried to elucidate in vitro the roles of factors such as 1) cells and 2) soluble 
mediators present at inflammation sites in the context of MSC homing. 
 
4.1 MSC-HUVEC interaction is mediated by VLA4 expressed on hfMSC 
 Our parallel plate flow chamber assay results showed that MSC can interact with 





observation was consistent with the study done by Ruster et al, who also documented 
similar interactions. In addition, they showed that MSC-HUVEC interactions were 
dependent on P-selectin and VCAM-1 expressed on the HUVEC through function 
blocking assays (Ruster et al., 2006). Consistent with this study, we showed that alpha 4 
integrin subunit played a more vital role than beta 1 integrin subunit in mediating 
hfMSC-HUVEC adhesion to HUVEC under defined flow conditions. Apart from the 
VLA4-VCAM-1 adhesive pathway, we were unable to detect a role for any other 
adhesion molecules in the tethering and binding of hfMSC to HUVEC under defined 
flow conditions. However, it has also been documented that alpha 4 integrin subunit can 
also dimerize with the beta 7 integrin subunit to form the receptor for Mucosal Addressin 
Cell Adhesion Molecule-1 (MAdCAM-1) (Gorfu et al., 2009). Alpha 4 beta 7 integrin is 
an important homing receptor found on lymphocytes and is responsible for the cells’ 
ability to selectively home to gut associated lymphoid tissues (Petrovic et al., 2004; 
Gorfu et al., 2009). MSC has been documented to express the mRNA but not the protein 
for beta 7 integrin (Brooke et al., 2008). However, it is not known if alpha 4 beta 7 
integrin plays a role in the recruitment of MSC. 
As integrins are documented to function as a heterodimer (Hynes, 1992), it is 
interesting to note that a single subunit is essential for the interaction while its partner 
appear uninvolved. This phenomenon had previously been reported in a rabbit model of 
acute inflammation after stent implantation, where inflammatory response was reduced 
by blocking alpha 4 integrin expressed on immune cells (Ma and O'Brien, 2004). Also, it 
is well documented that the beta integrin subunit plays a more important role in integrin 
signaling due to their larger cytoplasmic domain (Liu et al., 2000). Therefore, it is 
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possible that the integrin subunits within a heterodimer have slightly different functions 
under different conditions. In mediating hfMSC interactions with endothelial cells, our 
data suggests that the alpha subunit was more geared towards adhesion whereas the beta 
subunit was probably more adapted for signaling. 
 
4.2 PDGFR expression and signaling in hfMSC 
 Platelet-derived growth factor (PDGF) is one of the most potent cues for 
mesenchymal cell migration (Fielder et al., 2004). Therefore, it is of little surprise that it 
is also a migratory stimulus for MSC, which is considered a progenitor mesenchymal cell. 
Our study showed that hfMSC expressed PDGFRα on the cell surface with little or no 
surface expression of PDGFRβ. This is in contrast to a study reporting cell surface 
expression of both PDGFRα and PDGFRβ on MSC (Ball et al., 2007). However, there is 
a difference in the tissue source of the MSC used. The study by Ball et al obtained their 
bone marrow-derived MSC from adults ranging from 18 to 26 year old whereas our MSC 
were obtained from first and second trimester fetal bone marrow. Although both PDGFR 
promotes migration in murine fibroblasts (Yu et al., 2001), each receptor subtype has 
been documented to have specific functions in vivo (Betsholtz, 2004; Betsholtz et al., 
2001). For instance, PDGFRα signaling affects a large range of progenitor cells and has 
been implicated in developmental processes such as embryogenesis and organogenesis. 
Knock out models of PDGFRα was proven to be lethal to developing embryo. PDGFRβ 
signaling primarily mediates the recruitment of pericytes during vascular development. 
Therefore, hfMSC expressing only surface PDGFRα probably reflects their in vivo 
phenotype and function within the first and second trimester fetal bone marrow. 
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Intracellular FACS staining revealed the presence of PDGFRβ suggesting that hfMSC 
may externalize these intracellular receptors given the right environmental cues. 
 PDGFR can exist as homodimers, PDGFRαα or PDGFRββ; or as the PDGFRαβ 
heterodimer. There are quite a few ligands with specific affinities for each of the 
homodimer or heterodimer PDGFR. PDGF-AA selectively binds to PDGFRα 
homodimers while PDGF-BB binds to all PDGFR homodimers and heterodimers. PDGF-
AB and PDGF-CC which resemble each other in their binding affinity, recognize both the 
PDGFRα homodimers and PDGFRαβ heterodimers (Gilbertson et al., 2001). The last 
member of the PDGF family of ligands, PDGF-DD recognizes PDGFRββ homodimers 
although it also recognizes PDGFαβ heterodimers to a limited extent (Bergsten et al., 
2001). PDGFRα and PDGFRβ are receptor tyrosine kinases with different signaling 
pathways. After ligand binding and activation, PDGFRα downstream signaling depends 
mainly on PI3K pathway whereas PDGFRβ is more dependent on the MAP kinase 
pathway (Tallquist and Kazlauskas, 2004).   
 Our study involves the use of PDGF-AB in our in vitro model because it is the 
main PDGF isoform secreted by activated platelets at injury sites (Ross et al., 1990). 
Although PDGF-AB was generally able to invoke a migratory response across hfMSC 
from different donors, their responses were variable. This probably suggests that the 
ability of hfMSC to respond to PDGF-AB depends on the amount of surface PDGFRα 
that the cells express.  
We have not examined the intracellular pathways involved in PDGFR signaling in 
hfMSC in this work. However, studies have suggested that PDGFRα signaling results in 
RhoA activation and cofilin phosphorylation in MSC. These events ultimately lead to α-
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actin filament polymerization and enhanced migration. Conversely, PDGFRβ signaling 
leads to α-actin depolymerization and negative regulation of the contractile machinery 
(Ball et al., 2007). In another study, Yu et al sought to elucidate the effects of PDGFRα 
and PDGFRβ signaling by using receptor specific PDGF ligands. They proposed that 
although both receptor subtypes have a role to play in mesenchymal cell migration, 
PDGFRα signaling promotes mesenchymal cell migration via cofilin phosphorylation and 
actin polymerization while PDGFRβ signaling results in the suppression of cofilin 
phosphorylation which inhibits cell migration (Yu et al., 2001). 
 
4.3 Effects of TNFα on PDGFR expression and hfMSC migration 
The binding of TNFα to its surface bound receptor sets off complex signaling 
cascades within the cells regulating physiological processes such as proliferation, 
migration and apoptosis (Prins et al., 1997; Zhou et al., 2006). Similarly, the 
inflammatory process is regulated by the local concentration of pro-inflammatory 
cytokines such as IL-1β, IL-6 and TNFα as well as chemokines and chemoattractants 
which affect the cells present at both the cellular and functional levels (Barreiro et al., 
2010). As MSC expresses both types of TNF receptors (Kelly et al., 2010), it is of no 
surprise that the resulting signaling pathways through TNFα exposure can alter the 
binding potential of the cells to HUVEC or to ECM. 
 TNFα-treated hfMSC showed changes to their growth factor and chemokine 
receptors expression profile. Firstly, cell surface expression of PDGFRα was consistently 
reduced after TNFα treatment. There is a study that linked pro-inflammatory cytokines to 
the down-regulation of PDGFRα in osteoblasts (Kose et al., 1996). In addition, a recent 
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study showed that co-culturing MSC with HUVEC resulted in down-regulation of 
PDGFRα on the MSC (Finkenzeller et al., 2010). In both cases, the mechanism involved 
the activation of p38 MAP kinase pathway which decreased the PDGFRα mRNA 
stability via post-transcriptional modifications. In addition, it was noted that intracellular 
levels of chemokine and growth factor receptors were also decreased after hfMSC were 
treated with TNFα (Table 3.1, Panel B). Therefore, it is possible that TNFα signaling 
down-regulates the protein expression of these receptors via a p38 MAP kinase 
dependent pathway and the reduction in surface PDGFRα could be explained partly by 
the decrease in intracellular PDGFRα store. 
 Other than receptor expression, we also observed a change in hfMSC basal 
migratory response and their response towards PDGF-AB after TNFα treatment. At both 
10ng/ml and 1ng/ml of TNFα treatment, hfMSC exhibited increased motility in the 
absence of any chemoattractant compared to untreated cells. Gadea et al showed that 
short exposure to TNFα (within 10 minutes) activates the RhoGTPase, Cdc42, which 
promotes filopodia formation in mouse embryonic fibroblasts (Gadea et al., 2004). The 
study also reported that prolonged TNFα stimulation will activate p53 and p38 MAP 
kinase, resulting in the inhibition of filopodia formation. In another study conducted on 
embryonic stem cells (ESC), treatment with TNFα for up to 60 minutes phosphorylates 
p38 MAP kinase and JNK (Chen et al., 2003). In cells activated with TNFα beyond 60 
minutes, the level of phosphorylation is similar to baseline level. In all, these evidences 
probably suggest cell-type specific differences in TNFα signaling; and the subsequent 




 Interestingly, when hfMSC are exposed to both PDGF-AB and TNFα together, 
the migratory response of the untreated cells differs from that of TNFα pretreated cells. 
Response of untreated hfMSC towards PDGF-AB was reduced in the presence of TNFα, 
but prior TNFα treatment seemed to be able to desensitize the cells to the effect of TNFα. 
Studies have showed that TNFα signaling via p55/TNFRI results in the biosynthesis of a 
second messenger, ceramide (Ghosh et al., 1997). Ceramide is part of the 
sphingomyelin/ceramide/sphingosine-1-phosphate (Spm/Cer/S1P) signaling pathway 
which is involved in many different cellular processes such as proliferation and migration 
(Levade et al., 2001). Ceramide produced from TNFRI signaling has also been shown to 
desensitize cells to subsequent TNFα exposure (Ginis et al., 1999).  
It has been widely documented that although wound healing requires the action of 
inflammatory cytokines, excessive amount of these mediators may impede the process 
(Fajardo et al., 1992). In the wound healing assay, we did not observe any significant 
enhancement in the migratory response of TNFα-treated hfMSC. In addition, exposure to 
different soluble mediators did not cause any variation in the extent of cell migration. The 
main difference between the two assays is that a concentration gradient exists in the 
transwell assay but not in the wound healing assay. This data strongly suggests that 
concentration gradient effect plays a role in the migration of MSC. This is consistent with 
the study by DeLong et al who reported that the concentration gradient of growth factors 
is important in the chemotaxis of various cell-types (DeLong et al., 2005). However, the 
variations in observation might also be due to the different nature of the two assays. The 
transwell assay is a three-dimensional assay where MSC have to first invade the gelatin 
layer before they can squeeze and migrate through the pores of the membrane and the 
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invasion process might have an effect on the migration of the cells. The wound healing 
assay on the other hand, is a two-dimensional assay involving mainly cell migration. It 
was also noted that the absolute distance moved by the migrating front depended on the 
initial size of the wound; where larger wounds closed up more compared to smaller 
wounds. We found that the scratch size had a low reproducibility rate which resulted in 
the large standard error. 
 
4.4 Possible involvement of leukocytes in MSC recruitment  
The existence of circulating MSC is still very much a controversial topic. 
Inconsistent results have been reported in studies involving healthy donors as well as 
patients undergoing prior treatment with GM-CSF (Roufosse et al., 2004). It is likely that 
circulating MSC are probably found only in low number under physiological and non-
induced conditions. 
 To date, studies that tried to elucidate the mechanism of MSC recruitment have 
been only looking at the direct interactions between MSC and endothelial cells without 
considering the microenvironment in which the MSC is homing to (Ruster et al., 2006). 
Leukocytes are usually the first cell type to reach an injury or inflammatory site and it is 
unlikely that MSC recruitment could occur before the arrival of leukocytes (Martin and 
Leibovich, 2005). As such, it is very probable that the presence of trafficking leukocytes 
to the injury site may influence or contribute to MSC homing. 
 Leukocytes have been implicated in tumour metastasis by physically associating 
with tumour cells within the bloodstream for homing to target organs. Studies revealed 
that these interactions were mediated by L-selectins expressed on leukocytes (Läubli et 
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al., 2006). Similarly, P-selectin expressed on platelets has also been documented to play a 
role in tumour metastasis through interactions with carcinoma cell-surface mucin ligands 
(Borsig et al., 2001). MSC have been shown to possess a propensity to home to injured 
tissues (Chamberlain et al., 2007), thus it is possible that they might interact with 
leukocytes or platelets following mobilization from bone marrow. 
 Our study sought to exploit homing leukocytes to allow efficient MSC homing to 
injury sites as leukocytes are naturally adapted to home to inflamed tissues (Barreiro et 
al., 2010). Using this model, we are able to offer a plausible explanation for why MSC 
are able to recruit in vivo despite lacking expression of selectin ligands (Sackstein et al., 
2008) and surface chemokine receptors such as CXCR4 (Brooke et al., 2008; Phinney 
and Prockop, 2007).  
 There is increasing evidence pointing to TNFα being able to enhance adhesion 
and migration of MSC in animal models (Kim et al., 2009). Quite unexpectedly, we 
showed that pre-treatment of hfMSC with 10ng/ml TNFα resulted in the inhibition of 
MSC-HUVEC interaction under flow conditions. This was in contrast to other studies 
done in rat models where MSC pre-treated with TNFα resulted in increased adhesion on 
cardiac microvascular endothelial cells across all levels of sheer stress studied (Segers et 
al., 2006). In contrast with our work, the above study only TNFα-activated either the 
endothelial cells or the MSC but not both cell types prior to their flow chamber 
experiments. In addition, the MSC and endothelial cells from the above study were 
obtained from rats while the MSC and endothelial cells in our study were obtained from 
human donors. Therefore, the variations in experimental observations might have been 
contributed partly by differences in cell activation as well as cell sources.  
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 Our data showed that monocytes are able to rescue the inhibition of MSC-
HUVEC interactions caused by TNFα treatment. This suggests that MSC might be able 
to interact with monocytes, thus activating them in some way which would allow their 
adhesion to the endothelial cells. This interaction is specific because it is not seen with 
neutrophils. In our models as shown in Figure 4.1, TNFα activated hfMSC upregulates 
their surface expression of ICAM1 and VCAM1 and monocytes might be interacting with 
the latter via VLA4 (Figure 4.1). Neutrophils, on the other hand are not able to interact 
with VCAM1 since they do not express VLA4 (Kirveskari et al., 2000). In addition, their 
LFA1 tend to cluster upon arrest prior to transmigration (Shaw et al., 2004). Thus, there 
might not be sufficient LFA-1 on the apical surface of the neutrophils to interact with 
ICAM1 on the MSC. Finally, the observation that only monocytes and not neutrophils are 
able to interact with MSC may shed light on the optimal period when MSC are more 
readily recruited to wound sites. In all, more work will be required to find out how we 












































Figure 4.1 Hypothesized model of monocyte-mediated MSC recruitment 
Monocytes bind and adhere to activated endothelial cells using a range of adhesion 
molecules. TNFα activated MSC expresses high levels of ICAM-1 and  
VCAM-1 which they could utilize to first bind the monocytes and subsequently to the 
endothelial cells. 
 
4.5 Timeframe of administration 
 There has been observations that MSC engrafted in higher numbers under an 
acute setting compared to a chronic condition (Schenk et al., 2007). This may suggest the 
presence of differences within the microenvironment of the injury site. This differences 
may include soluble factors (Schenk et al., 2007) and type of cells present at the injury 
site (Frangogiannis et al., 2002). At an injury or inflammatory site, leukocytes are 
normally recruited under acute conditions (Barreiro et al., 2010; Frangogiannis et al., 
2002). Exogenously administered MSC might be homing to these sites by following the 
inflammatory cells which express adhesion molecules and chemokine receptors making 
them adept at homing (Butcher, 1991). In our model, we showed specific interactions 
between hfMSC and monocytes, thus providing an explanation as to how MSC can 
preferentially home to injury/inflamed sites over non-specific areas (Ortiz et al., 2003).  
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 Beneficial effects of MSC were also shown to be greater when cells were 
administered near the period of injury (Berry et al., 2006). However, this phenomenon 
seems to be dependent on the anatomical location of the injury as studies have shown 
variations in their results. For instance, for heart ailments such as myocardial infarction, 
MSC administration has to be as early as two hours for optimal recovery (Zhao et al., 
2006), while for optimal restoration of neurological function of the brain, administration 
of MSC after 24 hours seemed optimal (Li et al., 2000). Therefore, it seems that the 
timing for MSC administration would require optimization for reparation of different 
organs and diseases. 
 
4.6 Number of administered MSC 
 In the clinical trials involving the use of MSC, a large number of cells (ranging 
from 150 million to 300 million) is administered in each dose (Health, 2008). Therefore, 
it is logical to think that a larger number of administered MSC would result in more 
favourable outcome; this was proven otherwise. In a study done in a rat model of brain 
injury, high number of i.v. administered MSC had no added benefits compared to a lower 
number of administered cells (Wu et al., 2007). This suggests that the number of 
administered MSC is not the limiting factor and the process of MSC homing and 
engraftment maybe controlled by other factors. For instance, the anatomical site and 
nature of the disease may play a part in determining the composition of the milieu of 




4.7 Active recruitment versus passive entrapment 
 Though we were able to show a direct interaction between MSC and monocytes, 
which may result in MSC homing, this does not rule out the possibility of passive 
entrapment. At an inflammatory site, there is increased vascular permeability and slower 
blood flow to facilitate recruitment of inflammatory cells (Wilhelm, 1962; Barreiro et al., 
2010; Frangogiannis et al., 2002). As such, conditions within the vasculature at the injury 
site are likely to be congested, which may result in passive entrapment of MSC.  
 Taken together, our data suggests that MSC homing to an injury/inflammatory 
site may not be predominantly due to direct interactions between MSC and the 
endothelium.  
 
4.8 Future studies 
Future studies involving MSC recruitment would require the consideration of the 
role and influence of other cell types that are simultaneously recruited to injury as well as 
inflammatory sites. More work would have to be put into elucidating the events that 
occur following injury and inflammation, particularly the cell-cell interactions between 
the various cell-types present within the vasculature microenvironment. Our blocking 
studies showed that alpha 4 integrin but not beta 1 integrin was responsible for mediating 
tethering and adhesion on endothelial cells. It is unknown as to how alpha 4 integrin can 
function independent of beta 1 integrin. Therefore, it may be worthwhile examining the 
specific mechanisms underlying alpha 4 integrin binding to endothelial cells. When we 
can fully understand the mechanisms involved, we will be able to design feasible 
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